http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent 0001039065--06-30 2025 Q2 false http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember 0001039065 us-gaap:CommonStockMember 2024-12-31 0001039065 us-gaap:RetainedEarningsMember 2024-12-31 0001039065 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001039065 us-gaap:RetainedEarningsMember 2024-09-30 0001039065 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001039065 2024-09-30 0001039065 us-gaap:RetainedEarningsMember 2024-06-30 0001039065 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001039065 us-gaap:RetainedEarningsMember 2023-12-31 0001039065 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001039065 us-gaap:RetainedEarningsMember 2023-09-30 0001039065 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001039065 2023-09-30 0001039065 us-gaap:RetainedEarningsMember 2023-06-30 0001039065 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001039065 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-12-31 0001039065 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-09-30 0001039065 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-06-30 0001039065 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-12-31 0001039065 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-09-30 0001039065 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-06-30 0001039065 us-gaap:EmployeeStockOptionMember 2024-06-30 0001039065 osis:ShareBasedEmployeeCompensationPlansMember 2024-12-31 0001039065 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001039065 osis:PerformanceBasedRestrictedStockUnitsMember 2024-07-01 2024-12-31 0001039065 osis:PerformanceBasedRestrictedStockUnitsMember 2023-07-01 2023-12-31 0001039065 2025-01-01 2024-12-31 0001039065 us-gaap:FacilityClosingMember 2024-12-31 0001039065 us-gaap:EmployeeSeveranceMember 2024-12-31 0001039065 us-gaap:AcquisitionRelatedCostsMember 2024-12-31 0001039065 osis:ChargesRelatedToLitigationMember 2024-12-31 0001039065 us-gaap:FacilityClosingMember 2024-06-30 0001039065 us-gaap:EmployeeSeveranceMember 2024-06-30 0001039065 us-gaap:AcquisitionRelatedCostsMember 2024-06-30 0001039065 osis:ChargesRelatedToLitigationMember 2024-06-30 0001039065 osis:OtherOperationalEfficiencyActivitiesMember 2024-10-01 2024-12-31 0001039065 osis:HealthcareDivisionMember 2024-07-01 2024-12-31 0001039065 us-gaap:LeaseholdImprovementsMember 2024-12-31 0001039065 us-gaap:LandMember 2024-12-31 0001039065 us-gaap:FurnitureAndFixturesMember 2024-12-31 0001039065 us-gaap:EquipmentMember 2024-12-31 0001039065 us-gaap:ConstructionInProgressMember 2024-12-31 0001039065 us-gaap:ComputerSoftwareIntangibleAssetMember 2024-12-31 0001039065 us-gaap:ComputerEquipmentMember 2024-12-31 0001039065 us-gaap:BuildingAndBuildingImprovementsMember 2024-12-31 0001039065 osis:ComputerSoftwareImplementationInProcessMember 2024-12-31 0001039065 us-gaap:LeaseholdImprovementsMember 2024-06-30 0001039065 us-gaap:LandMember 2024-06-30 0001039065 us-gaap:FurnitureAndFixturesMember 2024-06-30 0001039065 us-gaap:EquipmentMember 2024-06-30 0001039065 us-gaap:ConstructionInProgressMember 2024-06-30 0001039065 us-gaap:ComputerSoftwareIntangibleAssetMember 2024-06-30 0001039065 us-gaap:ComputerEquipmentMember 2024-06-30 0001039065 us-gaap:BuildingAndBuildingImprovementsMember 2024-06-30 0001039065 osis:ComputerSoftwareImplementationInProcessMember 2024-06-30 0001039065 osis:ConvertibleSeniorNotesDue2029Member 2024-07-19 2024-07-19 0001039065 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-10-01 2024-12-31 0001039065 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-12-31 0001039065 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-10-01 2023-12-31 0001039065 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-12-31 0001039065 us-gaap:OperatingSegmentsMember osis:SecurityDivisionMember 2024-10-01 2024-12-31 0001039065 us-gaap:OperatingSegmentsMember osis:OptoelectronicsAndManufacturingDivisionMember 2024-10-01 2024-12-31 0001039065 us-gaap:OperatingSegmentsMember osis:HealthcareDivisionMember 2024-10-01 2024-12-31 0001039065 us-gaap:IntersegmentEliminationMember 2024-10-01 2024-12-31 0001039065 us-gaap:CorporateNonSegmentMember 2024-10-01 2024-12-31 0001039065 us-gaap:OperatingSegmentsMember osis:SecurityDivisionMember 2024-07-01 2024-12-31 0001039065 us-gaap:OperatingSegmentsMember osis:OptoelectronicsAndManufacturingDivisionMember 2024-07-01 2024-12-31 0001039065 us-gaap:OperatingSegmentsMember osis:HealthcareDivisionMember 2024-07-01 2024-12-31 0001039065 us-gaap:IntersegmentEliminationMember 2024-07-01 2024-12-31 0001039065 us-gaap:CorporateNonSegmentMember 2024-07-01 2024-12-31 0001039065 us-gaap:OperatingSegmentsMember osis:SecurityDivisionMember 2023-10-01 2023-12-31 0001039065 us-gaap:OperatingSegmentsMember osis:OptoelectronicsAndManufacturingDivisionMember 2023-10-01 2023-12-31 0001039065 us-gaap:OperatingSegmentsMember osis:HealthcareDivisionMember 2023-10-01 2023-12-31 0001039065 us-gaap:IntersegmentEliminationMember 2023-10-01 2023-12-31 0001039065 us-gaap:CorporateNonSegmentMember 2023-10-01 2023-12-31 0001039065 us-gaap:OperatingSegmentsMember osis:SecurityDivisionMember 2023-07-01 2023-12-31 0001039065 us-gaap:OperatingSegmentsMember osis:OptoelectronicsAndManufacturingDivisionMember 2023-07-01 2023-12-31 0001039065 us-gaap:OperatingSegmentsMember osis:HealthcareDivisionMember 2023-07-01 2023-12-31 0001039065 us-gaap:IntersegmentEliminationMember 2023-07-01 2023-12-31 0001039065 us-gaap:CorporateNonSegmentMember 2023-07-01 2023-12-31 0001039065 us-gaap:RetainedEarningsMember 2024-10-01 2024-12-31 0001039065 us-gaap:RetainedEarningsMember 2023-10-01 2023-12-31 0001039065 osis:OptoelectronicsAndManufacturingDivisionMember 2024-10-01 2024-12-31 0001039065 us-gaap:CorporateMember 2023-10-01 2023-12-31 0001039065 us-gaap:CorporateMember 2023-07-01 2023-12-31 0001039065 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember 2024-12-31 0001039065 us-gaap:RevolvingCreditFacilityMember 2024-12-31 0001039065 osis:TermLoanMember 2024-12-31 0001039065 us-gaap:LineOfCreditMember 2024-12-31 0001039065 osis:LettersOfCreditSubFacilityMember 2024-12-31 0001039065 us-gaap:TrademarksMember 2024-12-31 0001039065 us-gaap:TrademarksMember 2024-06-30 0001039065 osis:SecurityDivisionMember 2024-07-01 2024-12-31 0001039065 osis:OptoelectronicsAndManufacturingDivisionMember 2024-07-01 2024-12-31 0001039065 osis:HealthcareDivisionMember 2024-07-01 2024-12-31 0001039065 osis:SecurityDivisionMember 2024-12-31 0001039065 osis:OptoelectronicsAndManufacturingDivisionMember 2024-12-31 0001039065 osis:HealthcareDivisionMember 2024-12-31 0001039065 osis:SecurityDivisionMember 2024-06-30 0001039065 osis:OptoelectronicsAndManufacturingDivisionMember 2024-06-30 0001039065 osis:HealthcareDivisionMember 2024-06-30 0001039065 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-12-31 0001039065 us-gaap:PatentsMember 2024-12-31 0001039065 us-gaap:DevelopedTechnologyRightsMember 2024-12-31 0001039065 osis:CustomerRelationshipsOrderOrProductionBacklogMember 2024-12-31 0001039065 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-06-30 0001039065 us-gaap:PatentsMember 2024-06-30 0001039065 us-gaap:DevelopedTechnologyRightsMember 2024-06-30 0001039065 osis:CustomerRelationshipsOrderOrProductionBacklogMember 2024-06-30 0001039065 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-12-31 0001039065 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-12-31 0001039065 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001039065 us-gaap:EmployeeStockOptionMember 2024-12-31 0001039065 us-gaap:ForeignExchangeForwardMember 2024-12-31 0001039065 us-gaap:ForeignExchangeForwardMember 2024-06-30 0001039065 us-gaap:InterestRateSwapMember 2024-12-31 0001039065 us-gaap:InterestRateSwapMember 2024-06-30 0001039065 osis:ConvertibleSeniorNotesDue2029Member 2024-07-31 0001039065 osis:FiveConsecutiveBusinessDaysAfterSpecifiedPeriodMember 2024-07-01 2024-12-31 0001039065 osis:CalendarQuarterCommencingAfterQuarterEndedOnSeptember302024Member 2024-07-01 2024-12-31 0001039065 osis:ConvertibleSeniorNotesDue2029Member 2024-07-01 2024-12-31 0001039065 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember 2024-07-01 2024-12-31 0001039065 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember 2024-07-01 2024-12-31 0001039065 us-gaap:RevolvingCreditFacilityMember 2024-07-01 2024-12-31 0001039065 us-gaap:ServiceMember 2024-10-01 2024-12-31 0001039065 us-gaap:ProductMember 2024-10-01 2024-12-31 0001039065 us-gaap:ServiceMember 2024-07-01 2024-12-31 0001039065 us-gaap:ProductMember 2024-07-01 2024-12-31 0001039065 us-gaap:ServiceMember 2023-10-01 2023-12-31 0001039065 us-gaap:ProductMember 2023-10-01 2023-12-31 0001039065 us-gaap:ServiceMember 2023-07-01 2023-12-31 0001039065 us-gaap:ProductMember 2023-07-01 2023-12-31 0001039065 us-gaap:FairValueInputsLevel2Member 2024-12-31 0001039065 osis:ConvertibleSeniorNotesDue2029Member 2024-12-31 0001039065 osis:PrivatelyHeldProviderOfRadioFrequencyTechnologyMember 2024-12-31 0001039065 osis:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember osis:SecurityDivisionMember 2024-10-01 2024-12-31 0001039065 osis:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember osis:SecurityDivisionMember 2024-07-01 2024-12-31 0001039065 osis:CustomerNumber2Member us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember osis:SecurityDivisionMember 2024-07-01 2024-12-31 0001039065 osis:CustomerNumber1Member us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember osis:SecurityDivisionMember 2024-07-01 2024-12-31 0001039065 osis:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember osis:SecurityDivisionMember 2023-10-01 2023-12-31 0001039065 osis:CustomerNumber2Member us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember osis:SecurityDivisionMember 2023-07-01 2024-06-30 0001039065 osis:CustomerNumber1Member us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember osis:SecurityDivisionMember 2023-07-01 2024-06-30 0001039065 osis:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember osis:SecurityDivisionMember 2023-07-01 2023-12-31 0001039065 2023-12-31 0001039065 2023-06-30 0001039065 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-10-01 2024-12-31 0001039065 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-07-01 2024-12-31 0001039065 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-10-01 2023-12-31 0001039065 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-07-01 2023-12-31 0001039065 osis:OptoelectronicsAndManufacturingDivisionMember 2024-07-01 2024-12-31 0001039065 osis:PrivatelyHeldProviderOfCriticalMilitarySpaceAndSurveillanceSolutionsMember 2024-07-01 2024-12-31 0001039065 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001039065 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001039065 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2024-12-31 0001039065 osis:PrivatelyHeldProviderOfRadiationTechnologyMember 2023-10-31 0001039065 osis:PrivatelyHeldContractManufacturingBusinessMember 2023-12-01 2023-12-31 0001039065 osis:PrivatelyHeldProviderOfRadiationTechnologyMember 2023-10-01 2023-10-31 0001039065 us-gaap:CorporateMember 2024-10-01 2024-12-31 0001039065 osis:SecurityDivisionMember 2024-10-01 2024-12-31 0001039065 us-gaap:CorporateMember 2024-07-01 2024-12-31 0001039065 osis:SecurityDivisionMember 2024-07-01 2024-12-31 0001039065 osis:OtherOperationalEfficiencyActivitiesMember 2024-07-01 2024-12-31 0001039065 osis:SecurityDivisionMember 2023-10-01 2023-12-31 0001039065 osis:OtherOperationalEfficiencyActivitiesMember 2023-10-01 2023-12-31 0001039065 osis:OptoelectronicsAndManufacturingDivisionMember 2023-10-01 2023-12-31 0001039065 osis:SecurityDivisionMember 2023-07-01 2023-12-31 0001039065 osis:OtherOperationalEfficiencyActivitiesMember 2023-07-01 2023-12-31 0001039065 osis:OptoelectronicsAndManufacturingDivisionMember 2023-07-01 2023-12-31 0001039065 us-gaap:OperatingSegmentsMember osis:SecurityDivisionMember 2024-12-31 0001039065 us-gaap:OperatingSegmentsMember osis:OptoelectronicsAndManufacturingDivisionMember 2024-12-31 0001039065 us-gaap:OperatingSegmentsMember osis:HealthcareDivisionMember 2024-12-31 0001039065 us-gaap:IntersegmentEliminationMember 2024-12-31 0001039065 us-gaap:CorporateNonSegmentMember 2024-12-31 0001039065 us-gaap:OperatingSegmentsMember osis:SecurityDivisionMember 2024-06-30 0001039065 us-gaap:OperatingSegmentsMember osis:OptoelectronicsAndManufacturingDivisionMember 2024-06-30 0001039065 us-gaap:OperatingSegmentsMember osis:HealthcareDivisionMember 2024-06-30 0001039065 us-gaap:IntersegmentEliminationMember 2024-06-30 0001039065 us-gaap:CorporateNonSegmentMember 2024-06-30 0001039065 osis:ConvertibleSeniorNotesDue2029Member 2024-10-01 2024-12-31 0001039065 osis:ConvertibleSeniorNotesDue2029Member 2024-07-01 2024-12-31 0001039065 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-10-01 2024-12-31 0001039065 us-gaap:ResearchAndDevelopmentExpenseMember 2024-10-01 2024-12-31 0001039065 us-gaap:CostOfSalesMember 2024-10-01 2024-12-31 0001039065 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-01 2024-12-31 0001039065 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-12-31 0001039065 us-gaap:CostOfSalesMember 2024-07-01 2024-12-31 0001039065 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-10-01 2023-12-31 0001039065 us-gaap:ResearchAndDevelopmentExpenseMember 2023-10-01 2023-12-31 0001039065 us-gaap:CostOfSalesMember 2023-10-01 2023-12-31 0001039065 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-12-31 0001039065 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-12-31 0001039065 us-gaap:CostOfSalesMember 2023-07-01 2023-12-31 0001039065 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-10-01 2024-12-31 0001039065 us-gaap:RetainedEarningsMember 2024-07-01 2024-12-31 0001039065 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-07-01 2024-12-31 0001039065 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-10-01 2023-12-31 0001039065 us-gaap:RetainedEarningsMember 2023-07-01 2023-12-31 0001039065 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-07-01 2023-12-31 0001039065 srt:MinimumMember osis:PrivatelyHeldProviderOfCriticalMilitarySpaceAndSurveillanceSolutionsMember 2024-09-01 2024-09-30 0001039065 srt:MaximumMember osis:PrivatelyHeldProviderOfCriticalMilitarySpaceAndSurveillanceSolutionsMember 2024-09-01 2024-09-30 0001039065 us-gaap:CommonStockMember 2022-09-30 0001039065 srt:MinimumMember osis:PerformanceBasedRestrictedStockUnitsMember 2024-07-01 2024-12-31 0001039065 srt:MaximumMember osis:PerformanceBasedRestrictedStockUnitsMember 2024-07-01 2024-12-31 0001039065 us-gaap:RestrictedStockUnitsRSUMember osis:ShareBasedEmployeeCompensationPlansMember 2024-07-01 2024-12-31 0001039065 us-gaap:FacilityClosingMember 2024-07-01 2024-12-31 0001039065 us-gaap:EmployeeSeveranceMember 2024-07-01 2024-12-31 0001039065 us-gaap:AcquisitionRelatedCostsMember 2024-07-01 2024-12-31 0001039065 osis:ChargesRelatedToLitigationMember 2024-07-01 2024-12-31 0001039065 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember 2024-12-31 0001039065 2023-10-01 2023-12-31 0001039065 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001039065 us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001039065 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001039065 us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001039065 2023-07-01 2023-12-31 0001039065 osis:ConvertibleSeniorNotesDue2029Member 2024-07-01 2024-07-31 0001039065 osis:ConvertibleSeniorNotesDue2029Member 2024-12-31 0001039065 2024-12-31 0001039065 2024-06-30 0001039065 osis:OneCustomerMember osis:SecurityDivisionMember 2024-10-01 2024-12-31 0001039065 osis:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember osis:SecurityDivisionMember 2024-07-01 2024-12-31 0001039065 osis:OneCustomerMember osis:SecurityDivisionMember 2024-07-01 2024-12-31 0001039065 osis:OneCustomerMember osis:SecurityDivisionMember 2023-10-01 2023-12-31 0001039065 osis:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember osis:SecurityDivisionMember 2023-07-01 2024-06-30 0001039065 osis:OneCustomerMember osis:SecurityDivisionMember 2023-07-01 2023-12-31 0001039065 osis:PrivatelyHeldProviderOfCriticalMilitarySpaceAndSurveillanceSolutionsMember 2024-09-30 0001039065 osis:PrivatelyHeldProviderOfCriticalMilitarySpaceAndSurveillanceSolutionsMember 2024-10-01 2024-12-31 0001039065 osis:PrivatelyHeldProviderOfCriticalMilitarySpaceAndSurveillanceSolutionsMember 2024-09-01 2024-09-30 0001039065 2024-10-01 2024-12-31 0001039065 2025-01-21 0001039065 2024-07-01 2024-12-31 xbrli:shares iso4217:USD xbrli:pure osis:customer iso4217:USD xbrli:shares osis:D osis:segment iso4217:USS

Table of Contents

​

​

​

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

​

FORM 10-Q

​

(Mark One)

​

| ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

For the quarterly period ended December 31, 2024

​

OR

​

| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

For the transition period from to

​

Commission File Number 000-23125

​

OSI SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

​

​

​ | ​ | ​
Delaware |  | 33-0238801
(State or other jurisdiction of incorporation or organization) | ​ | (I.R.S. Employer Identification No.)

​

12525 Chadron Avenue

Hawthorne, California 90250

(Address of principal executive offices) (Zip Code)

​

(310) 978-0516

(Registrant’s telephone number, including area code)

​

N/A

(Former name, former address and former fiscal year, if changed since last report)

​

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock, $0.001 par value | ​ | OSIS | ​ | The Nasdaq Global Select Market

​

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

​

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

​

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

​

Large accelerated filer ☒ |  | Accelerated filer ☐
​ | ​ | ​
Non-accelerated filer ☐ | ​ | Smaller reporting company ☐
​ | ​ | ​
​ | ​ | Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

​

As of January 21, 2025, there were 16,799,283 shares of the registrant’s common stock outstanding.

​

​

​

​

Table of Contents

OSI SYSTEMS, INC.

INDEX

​ | ​ | PAGE
​ | ​ | ​
PART I — FINANCIAL INFORMATION | 3
​ | ​ | ​
Item 1 — | Financial Statements (Unaudited) | 3
​ | Condensed Consolidated Balance Sheets at June 30, 2024 and D ecember 31, 2024 | 3
​ | Condensed Consolidated Statements of Operations for the three and six months ended December 31, 2023 and 2024 | 4
​ | Condensed Consolidated Statements of Comprehensive Income for the t hree and six months ended December 31, 2023 and 2024 | 5
​ | Condensed Consolidated Statements of Stockholders’ Equity for the t hree and six months ended December 31, 2023 and 2024 | 6
​ | Condensed Consolidated Statements of Cash Flows for the six months ended December 31, 2023 and 2024 | 8
​ | Notes to Condensed Consolidated Financial Statements | 9
Item 2 — | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 25
Item 3 — | Quantitative and Qualitative Disclosures about Market Risk | 31
Item 4 — | Controls and Procedures | 31
​ | ​ | ​
PART II — OTHER INFORMATION | 32
Item 1 — | Legal Proceedings | 32
Item 1A — | Risk Factors | 32
Item 2 — | Unregistered Sales of Equity Securities and Use of Proceeds | 32
Item 3 — | Defaults Upon Senior Securities | 32
Item 4 — | Mine Safety Disclosures | 32
Item 5 — | Other Information | 32
Item 6 — | Exhibits | 33
Signatures | 34

​

​

2

Table of Contents

PART I—FINANCIAL INFORMATION

​

ITEM 1. FINANCIAL STATEMENTS

​

OSI SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(amounts in thousands, except share amounts and par value)

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30, | ​ | December 31,
​ |  | 2024 |  | 2024
ASSETS | ​ | ​ | ​ | ​ | ​ | ​
CURRENT ASSETS: | ​ | ​ | ​ | ​ | ​ | ​
Cash and cash equivalents | ​ | $ | 95,353 | ​ | $ | 101,633
Accounts receivable, net | ​ |  | 648,155 | ​ | ​ | 703,933
Inventories | ​ |  | 397,939 | ​ | ​ | 441,795
Prepaid expenses and other current assets | ​ |  | 74,077 | ​ | ​ | 77,208
Total current assets | ​ |  | 1,215,524 | ​ | ​ | 1,324,569
Property and equipment, net | ​ |  | 113,967 | ​ | ​ | 124,023
Goodwill | ​ |  | 351,480 | ​ | ​ | 382,166
Intangible assets, net | ​ |  | 139,529 | ​ | ​ | 181,954
Other assets | ​ |  | 115,508 | ​ | ​ | 118,202
Total assets | ​ | $ | 1,936,008 | ​ | $ | 2,130,914
LIABILITIES AND STOCKHOLDERS’ EQUITY | ​ | ​ | ​ | ​ | ​ | ​
CURRENT LIABILITIES: | ​ | ​ | ​ | ​ | ​ | ​
Bank lines of credit | ​ | $ | 384,000 | ​ | $ | 236,000
Current portion of long-term debt | ​ |  | 8,167 | ​ | ​ | 8,200
Accounts payable | ​ |  | 191,149 | ​ | ​ | 183,768
Accrued payroll and related expenses | ​ |  | 46,732 | ​ | ​ | 39,433
Advances from customers | ​ |  | 53,431 | ​ | ​ | 76,494
Other accrued expenses and current liabilities | ​ |  | 131,158 | ​ | ​ | 159,823
Total current liabilities | ​ |  | 814,637 | ​ | ​ | 703,718
Long-term debt, net | ​ |  | 129,383 | ​ | ​ | 466,560
Other long-term liabilities | ​ |  | 128,505 | ​ | ​ | 134,806
Total liabilities | ​ |  | 1,072,525 | ​ | ​ | 1,305,084
Commitments and contingencies (Note 10) | ​ | ​ | ​ | ​ | ​ | ​
STOCKHOLDERS’ EQUITY: | ​ | ​ | ​ | ​ | ​ | ​
Preferred stock, $0.001 par value—10,000,000 shares authorized; no shares issued or outstanding | ​ |  | — | ​ | ​ | —
Common stock, $0.001 par value—100,000,000 shares authorized; issued and outstanding, 17,055,497 shares at June 30, 2024 and 16,745,805 shares at December 31, 2024 | ​ |  | 24,289 | ​ | ​ | 8,933
Retained earnings | ​ |  | 861,230 | ​ | ​ | 848,372
Accumulated other comprehensive loss | ​ |  | (22,036) | ​ | ​ | (31,475)
Total stockholders’ equity | ​ |  | 863,483 | ​ | ​ | 825,830
Total liabilities and stockholders’ equity | ​ | $ | 1,936,008 | ​ | $ | 2,130,914

​

See accompanying notes to condensed consolidated financial statements.

​

3

Table of Contents

OSI SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(amounts in thousands, except per share data)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended December 31, | ​ | Six Months Ended December 31,
​ |  | 2023 |  | 2024 |  | 2023 |  | 2024
Net revenues: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Products | ​ | $ | 290,179 | ​ | $ | 333,671 | ​ | $ | 489,888 | ​ | $ | 589,479
Services | ​ |  | 83,056 | ​ | ​ | 86,149 | ​ | ​ | 162,557 | ​ | ​ | 174,348
Total net revenues | ​ |  | 373,235 | ​ | ​ | 419,820 | ​ | ​ | 652,445 | ​ | ​ | 763,827
Cost of goods sold: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Products | ​ |  | 187,385 | ​ | ​ | 224,087 | ​ | ​ | 324,368 | ​ | ​ | 394,509
Services | ​ |  | 44,549 | ​ | ​ | 48,582 | ​ | ​ | 88,031 | ​ | ​ | 100,665
Total cost of goods sold | ​ |  | 231,934 | ​ | ​ | 272,669 | ​ | ​ | 412,399 | ​ | ​ | 495,174
Gross profit | ​ |  | 141,301 | ​ | ​ | 147,151 | ​ | ​ | 240,046 | ​ | ​ | 268,653
Operating expenses: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Selling, general and administrative | ​ |  | 71,604 | ​ | ​ | 70,722 | ​ | ​ | 131,402 | ​ | ​ | 142,945
Research and development | ​ |  | 16,350 | ​ | ​ | 18,257 | ​ | ​ | 32,272 | ​ | ​ | 36,030
Restructuring and other charges, net | ​ |  | 1,026 | ​ | ​ | 215 | ​ | ​ | 1,492 | ​ | ​ | 1,393
Total operating expenses | ​ |  | 88,980 | ​ | ​ | 89,194 | ​ | ​ | 165,166 | ​ | ​ | 180,368
Income from operations | ​ |  | 52,321 | ​ | ​ | 57,957 | ​ | ​ | 74,880 | ​ | ​ | 88,285
Interest and other expense, net | ​ |  | (6,534) | ​ | ​ | (8,619) | ​ | ​ | (12,282) | ​ | ​ | (15,978)
Income before income taxes | ​ |  | 45,787 | ​ | ​ | 49,338 | ​ | ​ | 62,598 | ​ | ​ | 72,307
Provision for income taxes | ​ |  | (9,234) | ​ | ​ | (11,519) | ​ | ​ | (13,166) | ​ | ​ | (16,552)
Net income | ​ | $ | 36,553 | ​ | $ | 37,819 | ​ | $ | 49,432 | ​ | $ | 55,755
Earnings per share: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic | ​ | $ | 2.15 | ​ | $ | 2.26 | ​ | $ | 2.92 | ​ | $ | 3.33
Diluted | ​ | $ | 2.11 | ​ | $ | 2.22 | ​ | $ | 2.87 | ​ | $ | 3.27
Shares used in per share calculation: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic | ​ |  | 16,995 | ​ | ​ | 16,724 | ​ | ​ | 16,910 | ​ | ​ | 16,733
Diluted | ​ |  | 17,302 | ​ | ​ | 17,040 | ​ | ​ | 17,238 | ​ | ​ | 17,048

​

See accompanying notes to condensed consolidated financial statements.

​

4

Table of Contents

OSI SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)

(amounts in thousands)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Three Months Ended December 31, | ​ | Six Months Ended December 31,
​ |  | 2023 |  | 2024 |  | 2023 |  | 2024
Net income | ​ | $ | 36,553 | ​ | $ | 37,819 | ​ | $ | 49,432 | ​ | $ | 55,755
Other comprehensive income (loss): | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Foreign currency translation adjustment, net of tax | ​ |  | 5,395 | ​ | ​ | (9,463) | ​ | ​ | 2,223 | ​ | ​ | (8,282)
Net unrealized gain (loss) on derivatives, net of tax | ​ | ​ | (3,390) | ​ | ​ | 1,683 | ​ | ​ | (2,243) | ​ | ​ | (1,537)
Other, net of tax | ​ | ​ | 137 | ​ | ​ | 380 | ​ | ​ | 274 | ​ | ​ | 380
Other comprehensive income (loss) | ​ | ​ | 2,142 | ​ | ​ | (7,400) | ​ | ​ | 254 | ​ | ​ | (9,439)
Comprehensive income | ​ | $ | 38,695 | ​ | $ | 30,419 | ​ | $ | 49,686 | ​ | $ | 46,316

​

See accompanying notes to condensed consolidated financial statements.

​

5

Table of Contents

OSI SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED)

(amounts in thousands, except share data)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended December 31, 2023
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​
​ | ​ | Common Stock | ​ | ​ | ​ | ​ | Other | ​ | ​ | ​
​ |  | Number of |  | ​ | ​ |  | Retained |  | Comprehensive |  | ​ | ​
​ |  | Shares |  | Amount |  | Earnings |  | Loss |  | Total
Balance—September 30, 2023 |  | 16,987,842 | ​ | $ | 17 | ​ | $ | 745,955 | ​ | $ | (21,515) | ​ | $ | 724,457
Exercise of stock options |  | 9,737 | ​ | ​ | 764 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 764
Vesting of RSUs |  | 20,794 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Stock-based compensation expense |  | — | ​ | ​ | 7,328 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 7,328
Taxes paid related to net share settlement of equity awards |  | (6,734) | ​ | ​ | (801) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (801)
Net income |  | — | ​ | ​ | — | ​ | ​ | 36,553 | ​ | ​ | — | ​ | ​ | 36,553
Other comprehensive income |  | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,142 | ​ | ​ | 2,142
Balance—December 31, 2023 | ​ | 17,011,639 | ​ | $ | 7,308 | ​ | $ | 782,508 | ​ | $ | (19,373) | ​ | $ | 770,443

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended December 31, 2024
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​
​ | ​ | Common Stock | ​ | ​ | ​ | ​ | Other | ​ | ​ | ​
​ |  | Number of |  | ​ | ​ |  | Retained |  | Comprehensive |  | ​ | ​
​ |  | Shares |  | Amount |  | Earnings |  | Loss |  | Total
Balance—September 30, 2024 |  | 16,710,749 | ​ | $ | 17 | ​ | $ | 810,553 | ​ | $ | (24,075) | ​ | $ | 786,495
Exercise of stock options |  | 18,253 | ​ | ​ | 1,732 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,732
Vesting of RSUs |  | 24,988 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Stock-based compensation expense |  | — | ​ | ​ | 8,509 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 8,509
Taxes paid related to net share settlement of equity awards |  | (8,185) | ​ | ​ | (1,325) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (1,325)
Net income |  | — | ​ | ​ | — | ​ | ​ | 37,819 | ​ | ​ | — | ​ | ​ | 37,819
Other comprehensive loss |  | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (7,400) | ​ | ​ | (7,400)
Balance—December 31, 2024 | ​ | 16,745,805 | ​ | $ | 8,933 | ​ | $ | 848,372 | ​ | $ | (31,475) | ​ | $ | 825,830

​

​

6

Table of Contents

OSI SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED)

(amounts in thousands, except share data)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Six Months Ended December 31, 2023
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​
​ | ​ | Common Stock | ​ | ​ | ​ | ​ | Other | ​ | ​ | ​
​ |  | Number of |  | ​ | ​ |  | Retained |  | Comprehensive |  | ​ | ​
​ |  | Shares |  | Amount |  | Earnings |  | Loss |  | Total
Balance—June 30, 2023 |  | 16,755,772 | ​ | $ | 9,835 | ​ | $ | 735,957 | ​ | $ | (19,627) | ​ | $ | 726,165
Exercise of stock options |  | 14,489 | ​ | ​ | 1,184 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,184
Vesting of RSUs |  | 384,614 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Shares issued under employee stock purchase plan |  | 29,813 | ​ | ​ | 2,031 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,031
Stock-based compensation expense |  | — | ​ | ​ | 14,417 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 14,417
Taxes paid related to net share settlement of equity awards |  | (173,049) | ​ | ​ | (20,159) | ​ | ​ | (2,881) | ​ | ​ | — | ​ | ​ | (23,040)
Net income |  | — | ​ | ​ | — | ​ | ​ | 49,432 | ​ | ​ | — | ​ | ​ | 49,432
Other comprehensive income |  | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 254 | ​ | ​ | 254
Balance—December 31, 2023 | ​ | 17,011,639 | ​ | $ | 7,308 | ​ | $ | 782,508 | ​ | $ | (19,373) | ​ | $ | 770,443

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Six Months Ended December 31, 2024
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​
​ | ​ | Common Stock | ​ | ​ | ​ | ​ | Other | ​ | ​ | ​
​ |  | Number of |  | ​ | ​ |  | Retained |  | Comprehensive |  | ​ | ​
​ |  | Shares |  | Amount |  | Earnings |  | Loss |  | Total
Balance—June 30, 2024 | ​ | 17,055,497 | ​ | $ | 24,289 | ​ | $ | 861,230 | ​ | $ | (22,036) | ​ | $ | 863,483
Exercise of stock options | ​ | 19,210 | ​ | ​ | 1,802 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,802
Vesting of RSUs | ​ | 322,406 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Shares issued under employee stock purchase program | ​ | 31,143 | ​ | ​ | 2,329 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,329
Stock-based compensation expense | ​ | — | ​ | ​ | 14,931 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 14,931
Repurchase of common stock | ​ | (531,314) | ​ | ​ | (28,919) | ​ | ​ | (51,524) | ​ | ​ | — | ​ | ​ | (80,443)
Taxes paid related to net share settlement of equity awards | ​ | (151,137) | ​ | ​ | (5,499) | ​ | ​ | (17,089) | ​ | ​ | — | ​ | ​ | (22,588)
Net income | ​ | — | ​ | ​ | — | ​ | ​ | 55,755 | ​ | ​ | — | ​ | ​ | 55,755
Other comprehensive loss | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (9,439) | ​ | ​ | (9,439)
Balance—December 31, 2024 |  | 16,745,805 | ​ | $ | 8,933 | ​ | $ | 848,372 | ​ | $ | (31,475) | ​ | $ | 825,830

​

​

7

Table of Contents

OSI SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(amounts in thousands)

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Six Months Ended December 31,
​ |  | 2023 |  | 2024
CASH FLOWS FROM OPERATING ACTIVITIES | ​ | ​ | ​ | ​ | ​ |
Net income | ​ | $ | 49,432 | ​ | $ | 55,755
Adjustments to reconcile net income to net cash provided by (used in) operating activities, net of effects from acquisitions: | ​ | ​ | ​ | ​ | ​ | ​
Depreciation and amortization | ​ |  | 19,856 | ​ | ​ | 22,097
Stock-based compensation expense | ​ |  | 14,417 | ​ | ​ | 14,931
Provision for (recovery of) losses on accounts receivable | ​ | ​ | 2,352 | ​ | ​ | (395)
Deferred income taxes | ​ | ​ | (805) | ​ | ​ | (372)
Amortization of debt discount and issuance costs | ​ |  | — | ​ | ​ | 800
Other | ​ |  | 99 | ​ | ​ | 119
Changes in operating assets and liabilities—net of business acquisitions: | ​ | ​ | ​ | ​ | ​ | ​
Accounts receivable | ​ |  | 11,458 | ​ | ​ | (64,244)
Inventories | ​ |  | (103,309) | ​ | ​ | (44,173)
Prepaid expenses and other assets | ​ |  | (30,458) | ​ | ​ | (24,652)
Accounts payable | ​ |  | 24,365 | ​ | ​ | (12,261)
Accrued payroll and related expenses | ​ | ​ | (870) | ​ | ​ | (9,230)
Advances from customers | ​ |  | 18,227 | ​ | ​ | 23,393
Deferred revenue | ​ | ​ | (8,312) | ​ | ​ | 17,400
Other liabilities | ​ |  | (2,836) | ​ | ​ | 36,220
Net cash provided by (used in) operating activities | ​ |  | (6,384) | ​ | ​ | 15,388
CASH FLOWS FROM INVESTING ACTIVITIES | ​ | ​ | ​ | ​ | ​ | ​
Acquisition of property and equipment | ​ |  | (8,689) | ​ | ​ | (13,195)
Proceeds from sale of property and equipment | ​ | ​ | 167 | ​ | ​ | 114
Proceeds from maturities of certificates of deposit | ​ | ​ | 4,137 | ​ | ​ | 110
Acquisition of business, net of cash acquired | ​ |  | (9,046) | ​ | ​ | (75,500)
Payments for intangible and other assets | ​ |  | (8,376) | ​ | ​ | (9,088)
Net cash used in investing activities | ​ |  | (21,807) | ​ | ​ | (97,559)
CASH FLOWS FROM FINANCING ACTIVITIES | ​ | ​ | ​ | ​ | ​ | ​
Net borrowings (repayments) on bank lines of credit | ​ |  | 101,000 | ​ | ​ | (148,000)
Proceeds from long-term debt | ​ |  | 516 | ​ | ​ | 340,543
Payments on long-term debt | ​ |  | (4,172) | ​ | ​ | (4,130)
Proceeds from exercise of stock options and employee stock purchase plan | ​ |  | 3,215 | ​ | ​ | 4,131
Payment of contingent consideration | ​ | ​ | (464) | ​ | ​ | (331)
Repurchase of common stock | ​ |  | — | ​ | ​ | (80,443)
Taxes paid related to net share settlement of equity awards | ​ |  | (23,040) | ​ | ​ | (22,588)
Net cash provided by financing activities | ​ |  | 77,055 | ​ | ​ | 89,182
Effect of exchange rate changes on cash | ​ |  | 1,644 | ​ | ​ | (731)
Net increase in cash and cash equivalents | ​ |  | 50,508 | ​ | ​ | 6,280
Cash and cash equivalents—beginning of period | ​ |  | 76,750 | ​ | ​ | 95,353
Cash and cash equivalents—end of period | ​ | $ | 127,258 | ​ | $ | 101,633
Supplemental disclosure of cash flow information: | ​ | ​ | ​ | ​ | ​ | ​
Cash paid, net during the period for: | ​ | ​ | ​ | ​ | ​ | ​
Interest | ​ | $ | 11,567 | ​ | $ | 11,621
Income taxes | ​ | $ | 21,761 | ​ | $ | 18,106

​

See accompanying notes to condensed consolidated financial statements.

​

8

Table of Contents

OSI SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

​

1. Basis of Presentation

The condensed consolidated financial statements include the accounts of OSI Systems, Inc. and our subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and in conjunction with the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures required for annual financial statements have been condensed or excluded in accordance with SEC rules and regulations and GAAP applicable to interim unaudited financial statements. Accordingly, the condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for audited annual financial statements. In the opinion of management, the condensed consolidated financial statements reflect all adjustments of a normal and recurring nature that are considered necessary for a fair presentation of the results for the interim periods presented. These unaudited condensed consolidated financial statements and the accompanying notes should be read in conjunction with the audited consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 filed with the SEC. The results of operations for the three and six months ended December 31, 2024 are not necessarily indicative of the operating results to be expected for the full 2025 fiscal year or any future periods.

Use of Estimates

​

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of sales, costs of sales and expenses during the reporting period. The most significant of these estimates and assumptions for our company relate to contract revenue, fair values of assets acquired and liabilities assumed in business combinations, values for inventories reported at lower of cost or net realizable value, stock-based compensation expense, income taxes, accrued warranty costs, contingent consideration, allowance for doubtful accounts, and the recoverability, useful lives and valuation of recorded amounts of long-lived assets, identifiable intangible assets and goodwill. Changes in estimates are reflected in the periods during which they become known. Due to the inherent uncertainty involved in making estimates, our actual amounts reported in future periods could differ materially from estimated amounts.

​

Earnings Per Share Computations

​

We compute basic earnings per share by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period. We compute diluted earnings per share by dividing net income available to common stockholders by the sum of the weighted average number of common shares and dilutive potential common shares outstanding during the period. Potential common shares consist of the shares issuable upon the exercise of stock options and restricted stock unit awards under the treasury stock method. The underlying equity component of the 2.25% convertible senior notes due 2029 (the “2029 Notes”) discussed in Note 8 to the condensed consolidated financial statements will have a net impact on diluted earnings per share when the average price of our common stock exceeds the conversion price of $191.98 because the principal amount of the 2029 Notes will be settled in cash upon conversion. There was no dilutive effect of the 2029 Notes for the three and six months ended December 31, 2024.

​

9

Table of Contents

The following table sets forth the computation of basic and diluted earnings per share (in thousands, except per share amounts):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Three Months Ended December 31, |  | Six Months Ended December 31,
​ | ​ | 2023 |  | 2024 |  | 2023 |  | 2024
Net income available to common stockholders | ​ | $ | 36,553 | ​ | $ | 37,819 | ​ | $ | 49,432 | ​ | $ | 55,755
Weighted average shares outstanding—basic | ​ |  | 16,995 | ​ | ​ | 16,724 | ​ |  | 16,910 | ​ |  | 16,733
Dilutive effect of equity awards | ​ |  | 307 | ​ | ​ | 316 | ​ |  | 328 | ​ |  | 315
Weighted average shares outstanding—diluted | ​ |  | 17,302 | ​ | ​ | 17,040 | ​ |  | 17,238 | ​ |  | 17,048
Basic earnings per share | ​ | $ | 2.15 | ​ | $ | 2.26 | ​ | $ | 2.92 | ​ | $ | 3.33
Diluted earnings per share | ​ | $ | 2.11 | ​ | $ | 2.22 | ​ | $ | 2.87 | ​ | $ | 3.27
Shares excluded from diluted earnings per share due to their anti-dilutive effect | ​ | ​ | 10 | ​ | ​ | 9 | ​ | ​ | 5 | ​ | ​ | 5

​

Cash and Cash Equivalents

​

We consider all highly liquid investments with maturities of three months or less as of the acquisition date to be cash equivalents.

Our cash and cash equivalents totaled $101.6 million at December 31, 2024. Of this amount, approximately 77% was held by our foreign subsidiaries and subject to repatriation tax considerations. These foreign funds were held primarily by our subsidiaries in India, the United Kingdom and to a lesser extent in Malaysia, Singapore, and Canada, among other countries. We have cash holdings in financial institutions that exceed insured limits for such financial institutions; however, we mitigate this risk by utilizing international financial institutions which we believe to be of high credit quality.

​

Fair Value of Financial Instruments

​

Our financial instruments consist primarily of cash and cash equivalents, insurance company contracts, accounts receivable, accounts payable, debt instruments, an interest rate swap contract and foreign currency forward contracts. The carrying values of financial instruments, other than long-term debt instruments and the interest rate swap contract, are representative of their fair values due to their short-term maturities. The carrying values of our long-term debt instruments, other than the 2029 Notes, are considered to approximate their fair values because the interest rates of these instruments are variable or comparable to current rates for financing available to us. The fair value of the 2029 Notes are based on observable inputs described below under Level 2. The fair values of our foreign currency forward contracts were not significant as of June 30, 2024 and December 31, 2024.

​

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The “Level 1” category includes assets and liabilities measured at quoted prices in active markets for identical assets and liabilities. The “Level 2” category includes assets and liabilities measured from observable inputs other than quoted market prices. The “Level 3” category includes assets and liabilities for which valuation inputs are unobservable and significant to the fair value measurement. Our contingent payment obligations related to acquisitions, which are further discussed in Note 10 to the condensed consolidated financial statements, are in the “Level 3” category for valuation purposes.

​

The fair values of our financial assets and liabilities are categorized as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | June 30, 2024 |  | December 31, 2024
​ |  | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Level 1 |  | Level 2 |  | Level 3 |  | Total
Assets—Insurance company contracts | ​ | $ | — | ​ | $ | 49,679 | ​ | $ | — | ​ | $ | 49,679 | ​ | $ | — | ​ | $ | 52,428 | ​ | $ | — | ​ | $ | 52,428
Assets – Interest rate swap contract | ​ | $ | — | ​ | $ | 4,735 | ​ | $ | — | ​ | $ | 4,735 | ​ | $ | — | ​ | $ | 2,690 | ​ | $ | — | ​ | $ | 2,690
Liabilities—Convertible debt | ​ | $ | — | ​ | $ | — | ​ | $ | — | ​ | $ | — | ​ | $ | — | ​ | $ | 380,069 | ​ | $ | — | ​ | $ | 380,069
Liabilities—Contingent consideration | ​ | $ | — | ​ | $ | — | ​ | $ | 15,375 | ​ | $ | 15,375 | ​ | $ | — | ​ | $ | — | ​ | $ | 23,562 | ​ | $ | 23,562

​

10

Table of Contents

Derivative Instruments and Hedging Activity

​

Our use of derivatives consists of foreign currency forward contracts and an interest rate swap agreement. Our foreign currency forward contracts are utilized to partially mitigate certain balance sheet exposures or used as a net investment hedge to protect against potential changes resulting from short-term foreign currency fluctuations. These contracts have original maturities of up to three months. We also manage our risk to changes in interest rates using derivative instruments. We use fixed interest rate swaps to effectively convert a portion of the variable interest rate payments to fixed interest rate payments. We do not use hedging instruments for speculative purposes.

​

The net gains or losses from our foreign currency forward contracts, which are not designated as hedge instruments, are reported in our consolidated statements of operations. The amounts reported in the consolidated statements of operations for the three and six months ended December 31, 2023 and 2024 were not significant. The fair value of our foreign currency forward contracts is estimated using a standard valuation model and market-based observable inputs over the contractual term. Unrealized gains are recognized as assets and unrealized losses are recognized as liabilities. As of June 30, 2024 and December 31, 2024, we held foreign currency forward contracts with notional amounts totaling $96.4 million and $79.4 million, respectively. Unrealized gains and losses from our foreign currency forward contracts as of June 30, 2024 and December 31, 2024 were not significant.

Our interest rate swap agreement was entered into to improve the predictability of cash flows from interest payments related to our variable, Secured Overnight Financing Rate (“SOFR”) based debt. The interest rate swap matures in December 2026. The interest rate swap is considered an effective cash flow hedge, and as a result, the net gains or losses on such instrument are reported as a component of other comprehensive income (loss) in our consolidated financial statements and are reclassified as net income when the underlying hedged interest impacts earnings. A qualitative and quantitative assessment of the interest rate swap hedge effectiveness is performed on a quarterly basis, unless facts and circumstances indicate that the hedge may no longer be highly effective.

As of June 30, 2024 and December 31, 2024, the notional amount of the derivative instruments designated as an interest rate swap hedge was $175 million. The fair value of the interest rate swap contract as of as of June 30, 2024 and December 31, 2024 is recorded in Other assets within the consolidated balance sheet.

The effect of the cash flow hedges on other comprehensive income (loss) and earnings for the periods presented was as follows (in thousands):

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Three Months Ended December 31, |  | Six Months Ended December 31,
​ | ​ | 2023 |  | 2024 | ​ | 2023 |  | 2024
Total interest and other expense, net presented in the condensed consolidated statements of operations in which the effects of cash flow hedges are recorded | ​ | $ | (6,534) | ​ | $ | (8,619) | ​ | $ | (12,282) | ​ | $ | (15,978)
Gain (loss) recognized in other comprehensive income (loss), net of tax | ​ | $ | (3,390) | ​ | $ | 1,683 | ​ | $ | (2,243) | ​ | $ | (1,537)
Amount reclassified from accumulated other comprehensive income (loss) to interest expense, net | ​ | $ | 912 | ​ | $ | 635 | ​ | $ | 1,784 | ​ | $ | 1,535

​

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) and other regulatory bodies that are adopted as of the specified effective dates. Unless otherwise discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on our Consolidated Financial Statements upon adoption. There were no new pronouncements adopted in the first six months of fiscal year 2025.

In November 2023, the FASB issued Accounting Standards Update 2023-07, “Improvements to Reportable Segment Disclosures” (“ASU 2023-07”), which requires disclosures of significant expenses by segment and interim disclosure of items that were previously required on an annual basis. ASU 2023-07 is to be applied on a retrospective basis and is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024 with early adoption permitted. We are evaluating the potential impact of ASU 2023-07 on disclosures in our Consolidated Financial Statements which is effective beginning with our Form 10-K for fiscal year 2025 and interim periods beginning with the first quarter of fiscal year 2026.

In December 2023, the FASB issued Accounting Standards Update 2023-09, “Improvements to Income Tax Disclosures” (“ASU 2023-09”), which provides for additional disclosures primarily related to the income tax rate reconciliations and income taxes paid. ASU

11

Table of Contents

2023-09 requires entities to annually disclose the income tax rate reconciliation using both amounts and percentages, considering several categories of reconciling items, including state and local income taxes, foreign tax effects, tax credits and nontaxable or nondeductible items, among others. Disclosure of the reconciling items is subject to a quantitative threshold and disaggregation by nature and jurisdiction. ASU 2023-09 also requires entities to disclose net income taxes paid to or received from federal, state and foreign jurisdictions, as well as by individual jurisdiction, subject to a five percent quantitative threshold. ASU 2023-09 may be adopted on a prospective or retrospective basis and is effective for fiscal years beginning after December 15, 2024 with early adoption permitted. We are evaluating the potential impact of ASU 2023-09 on disclosures in our Consolidated Financial Statements which is effective beginning with our Form 10-K for fiscal year 2026.

2. Business Combinations

Under Accounting Standards Codification Topic 805, Business Combinations (“ASC 805”), the acquisition method of accounting requires us to record assets acquired less liabilities assumed from an acquisition at their estimated fair values at the date of acquisition. Any excess of the total estimated purchase price over the estimated fair value of the net assets acquired should be recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows from acquired customers, acquired technology, trade names, useful lives and discount rates. Management’s estimates of fair value are based upon assumptions which are believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. During the measurement period for fair value, which is up to one year from the acquisition date, as additional information that existed at the acquisition date becomes available, we may record adjustments to the preliminary assets acquired and liabilities assumed. Upon the conclusion of the measurement period, any subsequent adjustments are included in earnings.

Fiscal Year 2025 Business Acquisition

In September 2024, we (through our Security division) acquired 100% of the shares of common stock of a privately held provider of critical military, space and surveillance solutions to expand our customer base and offer additional products and services for existing customers, for approximately $76.0 million, plus up to $24.0 million in potential contingent consideration. We paid $75.5 million in cash at the closing of the transaction and recorded a holdback liability of $0.5 million which is expected to be released in November 2030. The cash paid for this acquisition was financed with borrowings from our credit facility. The acquisition date fair value of the contingent consideration was $9.7 million, therefore, when combined with the amount of cash paid at close and the holdback amount, total purchase consideration was $85.7 million which has been allocated to the preliminary fair value of assets acquired and liabilities assumed. The preliminary acquisition date fair value of total assets acquired, including measurement period adjustments, was $114.0 million which comprised accounts receivable of $26.6 million, inventory and other current assets of $4.7 million, property and equipment of $7.0 million, goodwill of $31.7 million, other intangible assets of $43.9 million and other noncurrent assets of $0.1 million. Goodwill includes the value of the assembled workforce, new customers and other future economic benefits which do not qualify for separate recognition. The goodwill recognized for this business acquisition is not deductible for income tax purposes. Other intangible assets include amortizable intangible assets of $35.9 million with amortization periods of 7 to 10 years and an indefinite-lived intangible asset of $8.0 million. The preliminary acquisition date fair value of total liabilities assumed, including measurement period adjustments, was $28.3 million, which includes a deferred tax liability of $7.5 million that was recognized primarily due to the acquisition of other intangible assets. The preliminary valuation of the assets acquired, liabilities assumed and contingent consideration in the acquisition is subject to revision. During the three months ended December 31, 2024, we recorded measurement period adjustments which increased goodwill by $3.3 million due to a decrease in net working capital of $4.2 million, net of deferred income taxes of $0.9 million. The measurement period adjustments did not have an impact on the consolidated statement of operations. If additional information becomes available, we may further revise the preliminary purchase price allocation as soon as practical, but no later than one year from the acquisition date. Revenue from this acquired business was $21.7 million from the acquisition date through December 31, 2024.

Fiscal Year 2024 Business Acquisitions

In December 2023, we (through our Optoelectronics and Manufacturing division) acquired a privately held contract manufacturer for approximately $6.3 million in cash. The acquisition was financed with cash on hand. The goodwill recognized for this business acquisition is deductible for income tax purposes.

In October 2023, we (through our Security division) acquired a privately held provider of radiation detection technology for approximately $2.8 million in cash, plus up to $3.6 million in potential contingent consideration. The acquisition was financed with cash on hand. The goodwill recognized for this business acquisition is not deductible for income tax purposes.

12

Table of Contents

3. Balance Sheet Details

​

The following tables set forth details of selected balance sheet accounts (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30, | ​ | December 31,
Accounts receivable, net |  | 2024 |  | 2024
Accounts receivable | ​ | $ | 667,227 | ​ | $ | 723,059
Less allowance for doubtful accounts | ​ |  | (19,072) | ​ | ​ | (19,126)
Total | ​ | $ | 648,155 | ​ | $ | 703,933

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30, | ​ | December 31,
Inventories |  | 2024 |  | 2024
Raw materials | ​ | $ | 238,086 | ​ | $ | 246,356
Work-in-process | ​ |  | 66,910 | ​ | ​ | 83,426
Finished goods | ​ |  | 92,943 | ​ | ​ | 112,013
Total | ​ | $ | 397,939 | ​ | $ | 441,795

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30, | ​ | December 31,
Property and equipment, net |  | 2024 |  | 2024
Land | ​ | $ | 15,494 | ​ | $ | 16,081
Buildings, civil works and improvements | ​ |  | 48,552 | ​ | ​ | 55,813
Leasehold improvements | ​ |  | 13,573 | ​ | ​ | 15,603
Equipment and tooling | ​ |  | 146,819 | ​ | ​ | 150,850
Furniture and fixtures | ​ |  | 3,348 | ​ | ​ | 3,561
Computer equipment | ​ |  | 22,597 | ​ | ​ | 24,331
Computer software | ​ |  | 29,195 | ​ | ​ | 31,725
Computer software implementation in process | ​ | ​ | 6,514 | ​ | ​ | 4,431
Construction in process | ​ |  | 6,986 | ​ | ​ | 7,520
Total | ​ |  | 293,078 | ​ | ​ | 309,915
Less accumulated depreciation and amortization | ​ |  | (179,111) | ​ | ​ | (185,892)
Property and equipment, net | ​ | $ | 113,967 | ​ | $ | 124,023

​

Depreciation and amortization expense for property and equipment was $4.6 million and $5.0 million for the three months ended December 31, 2023 and 2024, respectively, and $9.5 million and $11.7 million for the six months ended December 31, 2023 and 2024, respectively.

​

4. Goodwill and Intangible Assets

​

The changes in the carrying value of goodwill by segment for the six-month period ended December 31, 2024 were as follows (in thousands)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Optoelectronics | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | And | ​ | ​ | ​ | ​ | ​
​ | ​ | Security | ​ | Manufacturing | ​ | Healthcare | ​ | ​ | ​
​ |  | Division |  | Division |  | Division |  | Consolidated
Balance as of June 30, 2024 | ​ | $ | 232,215 | ​ | $ | 70,807 | ​ | $ | 48,458 | ​ | $ | 351,480
Goodwill acquired during the period (see Note 2) | ​ |  | 31,691 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 31,691
Foreign currency translation adjustment | ​ |  | (271) | ​ | ​ | (717) | ​ | ​ | (17) | ​ | ​ | (1,005)
Balance as of December 31, 2024 | ​ | $ | 263,635 | ​ | $ | 70,090 | ​ | $ | 48,441 | ​ | $ | 382,166

​

13

Table of Contents

Intangible assets consisted of the following (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30, 2024 | ​ | December 31, 2024
​ | ​ | Gross | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Gross | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Carrying | ​ | Accumulated | ​ | Intangibles | ​ | Carrying | ​ | Accumulated | ​ | Intangibles
​ |  | Value |  | Amortization |  | Net |  | Value |  | Amortization |  | Net
Amortizable assets: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Software development costs | ​ | $ | 79,228 | ​ | $ | (10,646) | ​ | $ | 68,582 | ​ | $ | 84,885 | ​ | $ | (9,088) | ​ | $ | 75,797
Patents | ​ | ​ | 9,116 | ​ | ​ | (3,861) | ​ | ​ | 5,255 | ​ | ​ | 9,364 | ​ | ​ | (4,092) | ​ | ​ | 5,272
Developed technology | ​ | ​ | 70,186 | ​ | ​ | (45,740) | ​ | ​ | 24,446 | ​ | ​ | 96,984 | ​ | ​ | (50,442) | ​ | ​ | 46,542
Customer relationships | ​ | ​ | 51,113 | ​ | ​ | (41,421) | ​ | ​ | 9,692 | ​ | ​ | 42,060 | ​ | ​ | (27,255) | ​ | ​ | 14,805
Total amortizable assets | ​ |  | 209,643 | ​ | ​ | (101,668) | ​ | ​ | 107,975 | ​ | ​ | 233,293 | ​ | ​ | (90,877) | ​ | ​ | 142,416
Non-amortizable assets: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Trademarks | ​ |  | 31,554 | ​ | ​ | — | ​ | ​ | 31,554 | ​ | ​ | 39,538 | ​ | ​ | — | ​ | ​ | 39,538
Total intangible assets | ​ | $ | 241,197 | ​ | $ | (101,668) | ​ | $ | 139,529 | ​ | $ | 272,831 | ​ | $ | (90,877) | ​ | $ | 181,954

​

Amortization expense related to intangible assets was $5.7 million and $5.6 million for the three months ended December 31, 2023 and 2024, respectively. Amortization expense related to intangible assets was $10.4 million for each of the six-month periods ended December 31, 2023 and 2024.

​

During the six months ended December 31, 2024, intangible assets of $43.9 million were from the business acquisition described in Note 2.

​

At December 31, 2024, the estimated future amortization expense for intangible assets was as follows (in thousands):

​

Fiscal Year

​

​ | ​ | ​ | ​
2025 (remaining 6 months) |  | $ | 10,388
2026 | ​ |  | 18,224
2027 | ​ |  | 16,766
2028 | ​ |  | 16,068
2029 | ​ | ​ | 13,953
Thereafter | ​ |  | 67,017
Total | ​ | $ | 142,416

​

Software development costs for software products incurred before establishing technological feasibility are charged to operations. Software development costs incurred after establishing technological feasibility are capitalized on a product-by-product basis until the product is available for general release to customers at which time amortization begins. Annual amortization, charged to cost of goods sold, is the amount computed using the ratio of current revenues for the developed product divided by total current and anticipated future revenues for that developed product. In the event that future revenues are not estimable, such costs are amortized on a straight-line basis over the remaining estimated economic life of the product. Amortizable assets that have not yet begun to be amortized are included in Thereafter in the table above. For the three months ended December 31, 2023 and 2024, we capitalized software development costs in the amounts of $4.0 million and $4.6 million, respectively. For the six months ended December 31, 2023 and 2024, we capitalized software development costs in the amounts of $8.0 million and $8.8 million, respectively.

5. Contract Assets and Liabilities

​

We enter into contracts to sell products and provide services, and we recognize contract assets and liabilities that arise from these transactions. We recognize revenue and corresponding accounts receivable according to ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). When we recognize revenue in advance of the point in time at which contracts give us the right to invoice a customer, we record this as unbilled revenue, which is included in accounts receivable, net, on our consolidated balance sheets. We may also receive consideration, per the terms of a contract, from customers prior to transferring control of goods to the customer. We record customer deposits as contract liabilities. Additionally, we may receive payments, most typically under service and warranty contracts, at the onset of the contract and before services have been performed. In such instances, we record a deferred revenue liability in either Other accrued expenses and current liabilities or Other long-term liabilities. We recognize these contract liabilities as sales after all revenue recognition criteria are met.

14

Table of Contents

​

The table below shows the balance of contract assets and liabilities as of June 30, 2024 and December 31, 2024, including the change between the periods. There were no substantial non-current contract assets for the periods presented.

Contract Assets (in thousands)

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | June 30, |  | December 31, |  | ​ | ​ |  | ​ |
​ |  | 2024 |  | 2024 |  | Change |  | % Change |
Unbilled revenue (included in accounts receivable, net) | ​ | $ | 338,944 | ​ | $ | 279,095 | ​ | $ | (59,849) | ​ | (18) | %

Contract Liabilities (in thousands)

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | June 30, |  | December 31, |  | ​ |  | ​ |
​ |  | 2024 |  | 2024 |  | Change |  | % Change | ​
Advances from customers | ​ | $ | 53,431 | ​ | $ | 76,494 | ​ | $ | 23,063 | ​ | 43 | %
Deferred revenue—current | ​ |  | 46,855 | ​ | ​ | 66,158 | ​ | ​ | 19,303 | ​ | 41 | %
Deferred revenue—long-term | ​ |  | 22,809 | ​ | ​ | 19,265 | ​ | ​ | (3,544) | ​ | (16) | %

​

Contract Assets. Contract assets decreased by $59.8 million due to decreases in unbilled revenue of $85.2 million primarily from the achievement of certain milestones in our Security division which gives us the right to invoice customers, partially offset by an increase of $25.4 million from the business acquisition described in Note 2.

​

Remaining Performance Obligations. Remaining performance obligations related to ASC 606 represent the portion of the transaction price allocated to performance obligations under an original contract with a term greater than one year which are fully or partially unsatisfied at the end of the period. As of December 31, 2024, the portion of the transaction price allocated to remaining performance obligations was approximately $776.1 million. We expect to recognize revenue on approximately 61% of the remaining performance obligations over the next 12 months, and the remainder is expected to be recognized thereafter. During the six months ended December 31, 2024, we recognized revenue of $51.5 million from contract liabilities existing at the beginning of the period.

​

Practical Expedients. In cases where we are responsible for shipping after the customer has obtained control of the goods, we have elected to treat the shipping activities as fulfillment activities rather than as separate performance obligations. Additionally, we have elected to capitalize the cost to obtain a contract only if the period of amortization would be longer than one year. We only give consideration to whether a customer agreement has a financing component if the period of time between transfer of goods and services and customer payment is greater than one year.

​

6. Leases

​

The components of operating lease expense were as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended December 31, |  | Six Months Ended December 31,
​ |  | 2023 |  | 2024 | ​ | 2023 |  | 2024
Operating lease cost | ​ | $ | 2,806 | ​ | $ | 2,805 | ​ | $ | 5,611 | ​ | $ | 5,618
Variable lease cost | ​ | ​ | 269 | ​ | ​ | 285 | ​ | ​ | 534 | ​ | ​ | 479
Short-term lease cost | ​ | ​ | 341 | ​ | ​ | 434 | ​ | ​ | 666 | ​ | ​ | 931
​ | ​ | $ | 3,416 | ​ | $ | 3,524 | ​ | $ | 6,811 | ​ | $ | 7,028

​

15

Table of Contents

Supplemental disclosures related to operating leases were as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Balance Sheet Category |  | June 30, 2024 |  | December 31, 2024 | ​
Operating lease ROU assets, net |  | Other assets | ​ | $ | 30,040 | ​ | $ | 29,242 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating lease liabilities, current portion |  | Other accrued expenses and current liabilities | ​ | $ | 9,706 | ​ | $ | 9,906 | ​
Operating lease liabilities, long-term |  | Other long-term liabilities | ​ | ​ | 21,127 | ​ | ​ | 20,034 | ​
Total operating lease liabilities | ​ | ​ | ​ | $ | 30,833 | ​ | $ | 29,940 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted average remaining lease term | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 3.6 years | ​
Weighted average discount rate | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 4.6 | %

​

Supplemental cash flow information related to operating leases was as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Six Months Ended December 31,
​ |  | 2023 |  | 2024
Cash paid for operating lease liabilities | ​ | $ | 6,222 | ​ | $ | 6,059
ROU assets obtained in exchange for new lease obligations | ​ |  | 3,453 | ​ | ​ | 2,887

​

Maturities of operating lease liabilities at December 31, 2024 were as follows (in thousands):

​

​ | ​ | ​ | ​
​ |  | December 31, 2024
Less than one year | ​ | $ | 10,792
1 – 2 years | ​ |  | 9,318
2 – 3 years | ​ |  | 6,215
3 – 4 years | ​ |  | 2,213
4 – 5 years | ​ |  | 1,164
Thereafter | ​ |  | 2,769
​ | ​ |  | 32,471
Less: imputed interest | ​ |  | (2,531)
Total lease liabilities | ​ | $ | 29,940

​

​

7. Restructuring and Other Charges

​

We endeavor to align our global capacity and infrastructure with demand by our customers as well as to fully integrate acquisitions and thereby improve operational efficiency.

​

During the three months ended December 31, 2024, we recognized $0.2 million in restructuring and other charges primarily for acquisition-related costs. During the six months ended December 31, 2024, we recognized $1.4 million in restructuring and other charges, which included $0.6 million in acquisition related costs, $0.2 million for facility closure costs for operational efficiency activities, and $0.6 million for employee terminations.

​

During the three months ended December 31, 2023, we recognized $1.0 million in restructuring and other charges, which included $0.2 million in acquisition related costs, $0.3 million in legal charges, $0.3 million for facility closure costs for operational efficiency improvements, and $0.2 million for employee terminations. During the six months ended December 31, 2023, we recognized $1.5 million in restructuring and other charges, which included $0.4 million in acquisition related costs, $0.4 million in legal charges, $0.3 million for facility closure costs for operational efficiency improvements, and $0.3 million for employee terminations.

​

16

Table of Contents

The following tables summarize restructuring and other charges (benefits), net for the periods set forth below (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended December 31, 2023
​ | ​ | ​ | ​ | ​ | Optoelectronics and | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Manufacturing | ​ | Healthcare | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Security Division |  | Division |  | Division |  | Corporate |  | Total
Acquisition-related costs | ​ | $ | 26 | ​ | $ | 190 | ​ | $ | — | ​ | $ | — | ​ | $ | 216
Employee termination costs | ​ |  | 137 | ​ |  | 42 | ​ |  | — | ​ |  | 10 | ​ |  | 189
Facility closures/consolidation | ​ |  | — | ​ |  | 293 | ​ |  | — | ​ |  | — | ​ |  | 293
Legal costs, net | ​ |  | 1 | ​ |  | — | ​ |  | — | ​ |  | 327 | ​ |  | 328
Total | ​ | $ | 164 | ​ | $ | 525 | ​ | $ | — | ​ | $ | 337 | ​ | $ | 1,026

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended December 31, 2024
​ | ​ | ​ | ​ | ​ | Optoelectronics and | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Manufacturing | ​ | Healthcare | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Security Division |  | Division |  | Division |  | Corporate |  | Total
Acquisition-related costs | ​ | $ | 19 | ​ | $ | — | ​ | $ | — | ​ | $ | 215 | ​ | $ | 234
Employee termination costs | ​ |  | (19) | ​ |  | 14 | ​ |  | — | ​ |  | — | ​ |  | (5)
Legal costs, net | ​ |  | — | ​ |  | (14) | ​ |  | — | ​ |  | — | ​ |  | (14)
Total | ​ | $ | — | ​ | $ | — | ​ | $ | — | ​ | $ | 215 | ​ | $ | 215

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Six Months Ended December 31, 2023
​ |  | ​ | ​ |  | Optoelectronics and |  | ​ |  | ​ | ​ |  | ​ | ​
​ | ​ | ​ | ​ | ​ | Manufacturing | ​ | Healthcare | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Security Division |  | Division |  | Division |  | Corporate |  | Total
Acquisition-related costs | ​ | $ | 235 | ​ | $ | 190 | ​ | $ | — | ​ | $ | — | ​ | $ | 425
Employee termination costs | ​ | ​ | 150 | ​ | ​ | 42 | ​ | ​ | — | ​ | ​ | 120 | ​ | ​ | 312
Facility closures/consolidation | ​ |  | — | ​ | ​ | 344 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 344
Legal costs, net | ​ |  | 51 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 360 | ​ | ​ | 411
Total | ​ | $ | 436 | ​ | $ | 576 | ​ | $ | — | ​ | $ | 480 | ​ | $ | 1,492

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Six Months Ended December 31, 2024
​ | ​ | ​ | ​ | ​ | Optoelectronics and | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Manufacturing | ​ | Healthcare | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Security Division |  | Division |  | Division |  | Corporate |  | Total
Acquisition-related costs | ​ | $ | 369 | ​ | $ | — | ​ | $ | — | ​ | $ | 215 | ​ | $ | 584
Employee termination costs | ​ | ​ | 104 | ​ | ​ | 319 | ​ | ​ | 152 | ​ | ​ | — | ​ | ​ | 575
Facility closures/consolidation | ​ | ​ | 6 | ​ | ​ | 242 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 248
Legal costs, net | ​ | ​ | — | ​ | ​ | (14) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (14)
Total | ​ | $ | 479 | ​ | $ | 547 | ​ | $ | 152 | ​ | $ | 215 | ​ | $ | 1,393

​

The accrued liability for restructuring and other charges is included in other accrued expenses and current liabilities in our condensed consolidated balance sheets. The changes in the accrued liability for restructuring and other charges for the six-month period ended December 31, 2024 were as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Facility | ​ | ​ | ​ | ​ | ​
​ | ​ | Acquisition- | ​ | Employee | ​ | Closure/ | ​ | Legal | ​ | ​ | ​
​ | ​ | Related | ​ | Termination | ​ | Consolidation | ​ | Costs and | ​ | ​ | ​
​ |  | Costs |  | Costs |  | Cost |  | Settlements |  | Total
Balance as of June 30, 2024 | ​ | $ | 496 | ​ | $ | 294 | ​ | $ | 227 | ​ | $ | 808 | ​ | $ | 1,825
Restructuring and other charges, net | ​ |  | 584 | ​ | ​ | 575 | ​ | ​ | 248 | ​ |  | (14) | ​ | ​ | 1,393
Payments and adjustments, net | ​ |  | (1,007) | ​ | ​ | (775) | ​ | ​ | (389) | ​ |  | (365) | ​ | ​ | (2,536)
Balance as of December 31, 2024 | ​ | $ | 73 | ​ | $ | 94 | ​ | $ | 86 | ​ | $ | 429 | ​ | $ | 682

​

​

17

Table of Contents

8. Borrowings

​

Revolving Credit Facility

​

Our senior secured credit facility comprises a term loan and a $600 million revolving credit facility which matures in December 2026. The revolving credit facility includes a $300 million sub-limit for letters of credit. Under certain circumstances and subject to certain conditions, we have the ability to increase the revolving credit facility by the greater of $250 million or such amount as would not cause our secured leverage ratio to exceed a specified level. Borrowings under the facility bear interest at SOFR plus a margin of 1.5% as of December 31, 2024 (which margin can range from 1.0% to 1.75% based on our consolidated net leverage ratio as defined in the credit facility). Letters of credit reduce the amount available to borrow under the credit facility by their face value amount. The unused portion of the facility bears a commitment fee of 0.20% as of December 31, 2024 (which fee can range from 0.10% to 0.25% based on our consolidated net leverage ratio as defined in the credit facility). Our borrowings under the credit agreement are guaranteed by certain of our U.S.-based subsidiaries and are secured by substantially all of our assets and substantially all the assets of certain of our subsidiaries. The credit facility contains various representations and warranties, affirmative, negative and financial covenants and events of default. As of December 31, 2024, there were $236 million of borrowings outstanding under the revolving credit facility, $78.6 million outstanding under the letters of credit sub-facility, and $131.9 million outstanding under the term loan. As of December 31, 2024, the amount available to borrow under the revolving credit facility was $285.4 million. Loan amounts under the revolving credit facility may be borrowed, repaid and re-borrowed during the term. The principal amount of each loan is due and payable in full on the maturity date. We have the right to repay each loan in whole or in part from time to time without penalty. It is our practice to routinely borrow and repay several times per year under the revolving facility and therefore, borrowings under the revolving credit facility are included in current liabilities. As of December 31, 2024, we were in compliance with all financial covenants under this credit facility. In September 2022, we entered into an interest rate swap in order to mitigate the interest rate risk on a portion of the interest payments expected to be made on the borrowings outstanding under the revolving credit facility and term loan. Refer to Note 1 for details.

2.25% Convertible Senior Notes Due 2029 (“2029 Notes”)

​

In July 2024, we issued an aggregate of $350.0 million principal amount of 2.25% convertible senior notes due in August 2029 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, at an issuance price equal to 97.5% of the principal amount. The 2029 Notes were issued pursuant to and are governed by an indenture dated July 19, 2024. The proceeds from the issuance of the 2029 Notes were $340.4 million, net of the issuance discount and debt issuance costs.

The 2029 Notes are unsecured obligations which bear regular interest at 2.25% per annum payable semiannually in arrears on February 1 and August 1 of each year, beginning on February 1, 2025. The 2029 Notes will mature on August 1, 2029, unless repurchased, redeemed, or converted in accordance with their terms prior to such date. The 2029 Notes are convertible into a combination of cash and shares of our common stock, at an initial conversion rate of 5.2090 shares of common stock per $1,000 principal amount of 2029 Notes, which is equivalent to an initial conversion price of approximately $191.98 per share of our common stock. The default settlement method is a combination settlement with a specified dollar amount of $1,000 per $1,000 principal amount of notes. The conversion rate is subject to customary adjustments for certain dilutive events. We may redeem for cash all or any portion of the 2029 Notes, at our option, on or after August 6, 2027 if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days at a redemption price equal to 100% of the principal amount of the 2029 Notes to be redeemed, plus accrued and unpaid interest up to the day before the redemption date. The holders may require us to repurchase the 2029 Notes upon the occurrence of certain fundamental change transactions at a redemption price equal to 100% of the principal amount of the 2029 Notes redeemed, plus accrued and unpaid interest up to the day before the redemption date.

Holders of the 2029 Notes may convert all or a portion of their 2029 Notes at their option prior to May 1, 2029, in multiples of $1,000 principal amounts, only under the following circumstances (i) during any calendar quarter commencing after the quarter ended on September 30, 2024 (and only during such calendar quarter), if our common stock price exceeds 130% of the conversion price for at least 20 trading days during the 30 consecutive trading days at the end of the prior calendar quarter; (ii) during the five consecutive business days immediately after any 10 consecutive trading day period in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (iii) upon the occurrence of specified corporate events or certain distributions on our common stock; or (iv) if we call any or all 2029 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the notes called for redemption.

18

Table of Contents

On or after May 1, 2029, the 2029 Notes are convertible at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. Holders of the 2029 Notes who convert the 2029 Notes in connection with a make-whole fundamental change, as defined in the indenture governing the 2029 Notes, or in connection with a redemption may be entitled to an increase in the conversion rate.

We accounted for the issuance of the 2029 Notes as a single liability measured at its amortized cost, as no other embedded features require bifurcation and recognition as derivatives. The following table is a summary of the 2029 Notes as of December 31, 2024 (in thousands):

​

​ | ​ | ​ | ​
​ |  | December 31,
​ | ​ | 2024
Principal amount | ​ | $ | 350,000
Unamortized debt discount and issuance costs | ​ |  | (8,755)
Net carrying amount | ​ | $ | 341,245
​ | ​ | ​ | ​
Fair value (Level 2) | ​ | $ | 380,069

​

The 2029 Notes were not eligible for conversion as of December 31, 2024. No sinking fund is provided for the 2029 Notes, which means that we are not required to redeem or retire them periodically. As of December 31, 2024 we were in compliance with applicable financial covenants under the indenture governing the 2029 Notes.

For the three months ended December 31, 2024, total interest expense for the 2029 Notes was $2.4 million, which consisted of $2.0 million of contractual interest expense and $0.4 million of amortization of debt discount and issuance costs. For the six months ended December 31, 2024, total interest expense for the 2029 Notes was $4.3 million, which consisted of $3.5 million of contractual interest expense and $0.8 million of amortization of debt discount and issuance costs. The unamortized debt issuance cost is amortized on the effective interest method over the life of the 2029 Notes.

Other Borrowings

​

Several of our foreign subsidiaries maintain bank lines of credit, denominated in local currencies and U.S. dollars, primarily for the issuance of letters of credit. As of December 31, 2024, $68.0 million was outstanding under these letter-of-credit facilities. As of December 31, 2024, the total amount available under these credit facilities was $22.8 million.

​

Long-term debt consisted of the following (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | June 30, | ​ | December 31,
​ |  | 2024 |  | 2024
Term loan | ​ | $ | 135,625 | ​ | $ | 131,875
2029 Notes, net | ​ | ​ | — | ​ | ​ | 341,245
Other long-term debt | ​ |  | 1,925 | ​ | ​ | 1,640
​ | ​ |  | 137,550 | ​ | ​ | 474,760
Less current portion of long-term debt | ​ |  | (8,167) | ​ | ​ | (8,200)
Long-term portion of debt | ​ | $ | 129,383 | ​ | $ | 466,560

​

Future principal payments of long-term debt by fiscal year as of December 31, 2024 are as follows (in thousands):

​

​ | ​ | ​ | ​
2025 (6 months remaining) |  | $ | 4,100
2026 | ​ |  | 8,156
2027 | ​ |  | 121,071
2028 | ​ |  | 183
2029 and thereafter | ​ |  | 341,250
Total | ​ | $ | 474,760

​

​

19

Table of Contents

9. Stockholders’ Equity

​

Stock-based Compensation

​

As of December 31, 2024, we maintained the Amended and Restated 2012 Incentive Award Plan (the “OSI Plan”) as a stock-based employee compensation plan.

​

We recorded stock-based compensation expense in the consolidated statements of operations as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended December 31, |  | Six Months Ended December 31,
​ |  | 2023 |  | 2024 | ​ | 2023 |  | 2024
Cost of goods sold | ​ | $ | 255 | ​ | $ | 226 | ​ | $ | 487 | ​ | $ | 470
Selling, general and administrative | ​ | ​ | 6,945 | ​ | ​ | 8,142 | ​ | ​ | 13,676 | ​ | ​ | 14,166
Research and development | ​ | ​ | 128 | ​ | ​ | 141 | ​ | ​ | 254 | ​ | ​ | 295
Stock-based compensation expense | ​ | $ | 7,328 | ​ | $ | 8,509 | ​ | $ | 14,417 | ​ | $ | 14,931

​

As of December 31, 2024, total unrecognized compensation cost related to share-based compensation grants under the OSI Plan were estimated at $1.4 million for stock options and $20.6 million for restricted stock units (“RSUs”). We expect to recognize these costs over a weighted average period of 2.4 years with respect to the stock options and 2.3 years with respect to the RSUs.

​

The following summarizes stock option activity during the six months ended December 31, 2024:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Weighted | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Average | ​ | Weighted-Average | ​ | Aggregate
​ | ​ | Number of | ​ | Exercise | ​ | Remaining Contractual | ​ | Intrinsic Value
​ |  | Options |  | Price |  | Term |  | (in thousands)
Outstanding at June 30, 2024 |  | 78,958 |  | $ | 97.87 |  | ​ | ​ | ​ | ​
Granted |  | 15,531 | ​ | ​ | 174.63 | ​ | ​ | ​ | ​ | ​
Exercised |  | (19,210) | ​ | ​ | 93.66 | ​ | ​ | ​ | ​ | ​
Expired or forfeited |  | (376) | ​ | $ | 106.70 | ​ | ​ | ​ | ​ | ​
Outstanding at December 31, 2024 |  | 74,903 | ​ | $ | 114.82 | ​ | 7.8 years | ​ | $ | 4,053
Exercisable at December 31, 2024 | ​ | 37,305 | ​ | $ | 93.41 |  | 6.5 years | ​ | $ | 2,761

​

The following summarizes RSU award activity during the six months ended December 31, 2024:

​

​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Weighted-
​ | ​ | ​ | ​ | Average
​ |  | Shares |  | Fair Value
Nonvested at June 30, 2024 |  | 391,591 | ​ | $ | 99.21
Granted |  | 294,932 | ​ | ​ | 150.70
Vested |  | (322,406) | ​ | ​ | 127.92
Forfeited |  | (3,375) | ​ | ​ | 100.04
Nonvested at December 31, 2024 |  | 360,742 | ​ | $ | 115.65

​

As of December 31, 2024, there were approximately 1.6 million shares available for grant under the OSI Plan. Under the terms of the OSI Plan, RSUs and restricted stock granted from the pool of shares available for grant reduce the pool by 1.87 shares for each award granted. RSUs and restricted stock forfeited and returned to the pool of shares available for grant increase the pool by 1.87 shares for each award forfeited.

​

We granted 75,988 and 80,682 performance-based RSUs during the six months ended December 31, 2023 and 2024, respectively. These performance-based RSU awards are contingent on the achievement of certain performance metrics. The payout related to these awards can range from zero to 376% of the original number of shares or units awarded. Compensation cost associated with these performance-based RSUs are recognized based on the estimated number of shares that we ultimately expect will vest. If the estimated number of shares to vest is revised in the future, then stock-based compensation expense will be adjusted accordingly.

​

20

Table of Contents

Stock Repurchase Program

​

In September 2022, our Board of Directors increased the stock repurchase authorization to a total of 2 million shares. This program does not expire unless our Board of Directors acts to terminate the program. The timing and actual numbers of shares purchased depend on a variety of factors, including stock price, general business and market conditions and other investment opportunities. Repurchases may be made from time to time under the program through open-market purchases or privately-negotiated transactions at our discretion. Upon repurchase, the shares are restored to the status of authorized but unissued shares, and we record them in our consolidated financial statements as a reduction in the number of shares of common stock issued and outstanding, with the excess purchase price over par value recorded as a reduction of additional paid-in capital. If additional paid-in capital is reduced to zero, we record the remainder of the excess purchase price over par value as a reduction of retained earnings.

​

During the six months ended December 31, 2024, we repurchased 531,314 shares of common stock for an aggregate purchase price of approximately $80 million. As of December 31, 2024, there were 1,190,556 shares remaining available for repurchase under the authorized repurchase program.

​

Dividends

​

We have not paid any cash dividends since the consummation of our initial public offering in 1997, and we do not currently intend to pay any cash dividends in the foreseeable future. Our Board of Directors will determine the payment of future cash dividends, if any. Certain of our current bank credit facilities restrict the payment of cash dividends and future borrowings may contain similar restrictions.

​

10. Commitments and Contingencies

​

Acquisition-Related Contingent Obligations

​

Under the terms and conditions of the purchase agreements associated with certain acquisitions, we may be obligated to make additional payments based on the achievement of certain sales or profitability milestones through the acquired operations. The potential future payments for two agreements with uncapped contingent consideration through fiscal year 2028 are not expected to be significant. For agreements that contain contingent consideration obligations that are capped, the remaining maximum amount of such potential future payments is $56.5 million as of December 31, 2024.

​

Projections and estimated probabilities are used to estimate future contingent earnout payments, which are discounted back to present value to compute contingent earnout liabilities. The following table provides a roll-forward from June 30, 2024 to December 31, 2024 of the contingent consideration liability, which is included in other accrued expenses and current liabilities and other long-term liabilities in our consolidated balance sheets (in thousands):

​

​ | ​ | ​ | ​
Beginning fair value, June 30, 2024 |  | $ | 15,375
Business acquisition (Note 2) | ​ | ​ | 9,730
Foreign currency translation adjustment | ​ | ​ | (54)
Changes in fair value for contingent earnout obligations | ​ |  | (1,158)
Payments on contingent earnout obligations | ​ |  | (331)
Ending fair value, December 31, 2024 | ​ | $ | 23,562

​

Environmental Contingencies

​

We are subject to various environmental laws. We conduct environmental investigations at our manufacturing facilities in North America, Asia-Pacific, and Europe, and, to the extent practicable, on new properties in order to identify, as of the date of such investigation, potential areas of environmental concern related to past and present activities or from nearby operations. In certain cases, we have conducted further environmental assessments consisting of soil and groundwater testing and other investigations deemed appropriate by independent environmental consultants.

​

We have not accrued for loss contingencies relating to environmental matters because we believe that, although unfavorable outcomes are possible, they are not considered by our management to be probable and reasonably estimable. If one or more of these environmental matters are resolved in a manner adverse to us, the impact on our business, financial condition, results of operations and cash flow could be material.

21

Table of Contents

​

Indemnifications

​

In the normal course of business, we have agreed to indemnify certain parties with respect to certain matters. We have agreed to hold certain parties harmless against losses arising from a breach of representations, warranties or covenants, or intellectual property infringement or other claims made by third parties. These agreements may limit the time within which an indemnification claim can be made and the amount of the claim. In addition, we have entered into indemnification agreements with our directors and certain of our officers. It is not possible to determine the maximum potential amount under these indemnification agreements due to, among other factors, the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. We have not recorded any liability for costs related to contingent indemnification obligations as of December 31, 2024.

​

Product Warranties

​

We offer our customers warranties on many of the products that we sell. These warranties typically provide for repairs and maintenance of the products if problems arise during a specified time period after original shipment. Concurrent with the sale of products, we record a provision for estimated warranty expenses with a corresponding increase in cost of goods sold. We periodically adjust this provision based on historical experience and anticipated expenses. We charge actual expenses of repairs under warranty, including parts and labor, to this provision when incurred. The current obligation for warranty provision is included in other accrued expenses and current liabilities and the noncurrent portion is included in other long-term liabilities in the consolidated balance sheets.

​

The following table presents changes in warranty provisions (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Six Months Ended December 31,
​ |  | 2023 |  | 2024
Balance at beginning of period | ​ | $ | 11,149 | ​ | $ | 11,089
Additions | ​ | ​ | 1,417 | ​ | ​ | 2,553
Reductions for warranty repair costs and adjustments | ​ |  | (2,070) | ​ | ​ | (2,199)
Balance at end of period | ​ | $ | 10,496 | ​ | $ | 11,443

​

Legal Proceedings

In February 2023, one of our subsidiaries received a subpoena from the U.S. Department of Justice (“DoJ”). The subpoena was issued as part of a DoJ case against a former employee of an OSI Systems subsidiary for embezzlement and other conduct occurring before he was hired by our subsidiary and while he was employed by another company in the United States and Mexico. The subpoena requests documents and records relating to, among other things, the former employee and the Company’s business dealings in Mexico since 2020. In February 2024, we received a follow-up subpoena requesting the same categories of documents but extending the relevant time period through to the date of the second subpoena. We have produced documents in response to these subpoenas and intend to cooperate with any further subpoenas or other requests in connection with this or any ensuing investigation. In September 2024, we received a subpoena requesting records relating to certain entities in Honduras. Consistent with past practice, we intend to cooperate with requests arising from this most recent subpoena.

We are involved in various other potential or actual claims and legal proceedings arising in the ordinary course of business. In our opinion after consultation with legal counsel, the ultimate disposition of such proceedings is not likely to have a material adverse effect on our business, financial condition, results of operations or cash flows. We have not accrued for loss contingencies relating to any non-ordinary course matters because we believe that, although unfavorable outcomes in the proceedings are possible, they are not considered by management to be probable and reasonably estimable. If one or more of these matters are resolved in a manner adverse to our Company, the impact on our business, financial condition, results of operations and cash flows could be material.

​

11. Income Taxes

​

The determination of the annual effective tax rate is based upon a number of significant estimates and judgments, including the estimated annual pretax income in each tax jurisdiction in which we operate and the development of tax planning strategies during the year. In addition, as a global commercial enterprise, our tax expense can be impacted by changes in tax rates or laws, the finalization of tax audits and reviews and other factors that cannot be predicted with certainty. As such, there can be significant volatility in interim tax provisions.

22

Table of Contents

​

The effective tax rates for the six months ended December 31, 2023 and 2024 were 21.0% and 22.9%, respectively. During the six months ended December 31, 2023, we recognized a net discrete tax benefit of $0.6 million, related to equity-based compensation under ASU 2016-09 and a benefit of $2.3 million from changes in prior year tax estimates. During the six months ended December 31, 2024 we recognized a net discrete tax benefit of $0.8 million, related to equity-based compensation under ASU 2016-09.

​

12. Segment Information

​

We have determined that we operate in three identifiable industry segments: (a) security and inspection systems (Security division), (b) optoelectronic devices and manufacturing (Optoelectronics and Manufacturing division) and (c) medical monitoring systems (Healthcare division). We also have a corporate segment (Corporate) that includes executive compensation and certain other general and administrative expenses, expenses related to stock issuances and legal, audit and other professional service fees not allocated to industry segments. Both the Security and Healthcare divisions comprise primarily end-product businesses, whereas the Optoelectronics and Manufacturing division primarily supplies components and subsystems to external OEM customers, as well as to the Security and Healthcare divisions. Sales between divisions are at transfer prices that approximate market values. All other accounting policies of the segments are the same as described in Note 1, Basis of Presentation.

The following tables present our results of operations and identifiable assets by industry segment (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Six Months Ended
​ | ​ | December 31, | ​ | December 31,
​ |  | 2023 |  | 2024 |  | 2023 |  | 2024
Revenues (1), (2) —by Segment: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Security division | ​ | $ | 249,975 | ​ | $ | 289,987 | ​ | $ | 414,604 | ​ | $ | 514,301
Optoelectronics and Manufacturing division, including intersegment revenues | ​ | ​ | 98,097 | ​ | ​ | 100,743 | ​ | ​ | 194,225 | ​ | ​ | 198,538
Healthcare division | ​ | ​ | 41,850 | ​ | ​ | 44,854 | ​ | ​ | 79,637 | ​ | ​ | 81,956
Intersegment revenues elimination | ​ | ​ | (16,687) | ​ | ​ | (15,764) | ​ | ​ | (36,021) | ​ | ​ | (30,968)
Total | ​ | $ | 373,235 | ​ | $ | 419,820 | ​ | $ | 652,445 | ​ | $ | 763,827
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Income (loss) from operations —by Segment: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Security division | ​ | $ | 51,856 | ​ | $ | 54,053 | ​ | $ | 72,465 | ​ | $ | 82,909
Optoelectronics and Manufacturing division | ​ | ​ | 11,621 | ​ | ​ | 12,282 | ​ | ​ | 23,058 | ​ | ​ | 22,891
Healthcare division | ​ | ​ | 429 | ​ | ​ | 1,722 | ​ | ​ | 593 | ​ | ​ | 2,522
Corporate | ​ | ​ | (11,183) | ​ | ​ | (9,670) | ​ | ​ | (21,099) | ​ | ​ | (19,180)
Intersegment eliminations | ​ | ​ | (402) | ​ | ​ | (430) | ​ | ​ | (137) | ​ | ​ | (857)
Total | ​ | $ | 52,321 | ​ | $ | 57,957 | ​ | $ | 74,880 | ​ | $ | 88,285

​

23

Table of Contents

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30, | ​ | December 31,
​ |  | 2024 |  | 2024
Assets (3) —by Segment: | ​ | ​ | ​ | ​ | ​ | ​
Security division | ​ | $ | 1,333,259 | ​ | $ | 1,524,165
Optoelectronics and Manufacturing division | ​ |  | 288,629 | ​ | ​ | 275,135
Healthcare division | ​ | ​ | 255,093 | ​ | ​ | 268,376
Corporate | ​ |  | 106,078 | ​ | ​ | 109,489
Eliminations (4) | ​ |  | (47,051) | ​ | ​ | (46,251)
Total | ​ | $ | 1,936,008 | ​ | $ | 2,130,914

(1)For the three and six-month periods ended December 31, 2023, one customer in the Security division accounted for 18% and 14%, respectively, of consolidated net revenues.
(2)For the three and six-month periods ended December 31, 2024, one customer in the Security division accounted for 10% and 12%, respectively, of consolidated net revenues.
(3)As of June 30, 2024, two customers in the Security division accounted for 39% and 10%, respectively, of accounts receivable, net. As of December 31, 2024, two customers in the Security division accounted for 37% and 13%, respectively, of accounts receivable, net.
(4)Eliminations in assets reflect the amount of inter-segment profits in inventory and inter-segment ROU assets under ASC 842 as of the balance sheet date. Such inter-segment profit will be realized when inventory is shipped to the external customers of the Security and Healthcare divisions.

​

24

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

​

In this report, “OSI”, the “Company”, “we”, “us”, “our” and similar terms refer to OSI Systems, Inc. together with our wholly-owned subsidiaries.

​

This management’s discussion and analysis of financial condition as of December 31, 2024 and results of operations for the three and six months ended December 31, 2024 should be read in conjunction with management’s discussion and analysis of financial condition and results of operations included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 filed with the SEC.

​

Forward-Looking Statements

​

This report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements relate to our current expectations, beliefs, and projections concerning matters that are not historical facts. Words such as “project,” “believe,” “anticipate,” “plan,” “expect,” “intend,” “may,” “should,” “will,” “would,” and similar words and expressions are intended to identify forward-looking statements. Forward-looking statements are not guarantees of future performance and involve uncertainties, risks, assumptions and contingencies, many of which are outside our control. Assumptions upon which our forward-looking statements are based could prove to be inaccurate, and actual results may differ materially from those expressed in or implied by such forward-looking statements. Important factors that could cause our actual results to differ materially from our expectations are disclosed in this report, our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 (including Part I, Item 1, “Business,” Part I, Item 1A, “Risk Factors” and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”) and other documents filed by us from time to time with the SEC. Such factors, of course, do not include all factors that might affect our business and financial condition. We could be exposed to a variety of negative consequences as a result of delays related to the award of domestic and international contracts; failure to secure the renewal of key customer contracts; delays in customer programs; delays in revenue recognition related to the timing of customer acceptance; the impact of potential information technology, cybersecurity or data security breaches; changes in domestic and foreign government spending, budgetary, procurement and trade policies adverse to our businesses; the impact of the Russia-Ukraine conflict or conflicts in the Middle East, including the potential for broad economic disruption; global economic uncertainty; material delays and cancellations of orders or deliveries thereon, supply chain disruptions, plant closures, or other adverse impacts on our ability to execute business plans; unfavorable currency exchange rate fluctuations; effect of changes in tax legislation; market acceptance of our new and existing technologies, products and services; our ability to win new business and convert any orders received to sales within the fiscal year; contract and regulatory compliance matters, and actions, which if brought, could result in judgments, settlements, fines, injunctions, debarment or penalties; as well as other risks and uncertainties, including but not limited to those factors described in our other SEC filings. All forward-looking statements contained in this report are qualified in their entirety by this Section. Moreover, we operate in a very competitive and rapidly changing environment and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Investors should not place undue reliance on forward-looking statements as a prediction of actual results. We undertake no obligation other than as may be required under securities laws to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

​

Executive Summary

​

We are a vertically integrated designer and manufacturer of specialized electronic systems and components for critical applications. We sell our products and provide related services in diversified markets, including homeland security, healthcare, defense and aerospace. We have three operating divisions: (a) Security, providing security and inspection systems and turnkey security screening solutions; (b) Optoelectronics and Manufacturing, providing specialized electronic components for our Security and Healthcare divisions, as well as to third parties for applications in the defense and aerospace markets, among others; and (c) Healthcare, providing patient monitoring, cardiology and remote monitoring, and connected care systems and associated accessories.

​

Security Division. Through our Security division, we provide security screening products and services globally, as well as turnkey security screening solutions and high-powered radio frequency solutions. These products and services are used to inspect baggage, parcels, cargo, people, vehicles and other objects for weapons, explosives, drugs, radioactive and nuclear materials and other contraband.

25

Table of Contents

Revenues from our Security division accounted for 64% and 67% of our total consolidated revenues for the six months ended December 31, 2023 and 2024, respectively.

Optoelectronics and Manufacturing Division. Through our Optoelectronics and Manufacturing division, we design, manufacture and market optoelectronic devices and flex circuits and provide electronics manufacturing services globally for use in a broad range of applications, including aerospace and defense electronics, security and inspection systems, medical imaging and diagnostics, telecommunications, office automation, computer peripherals, industrial automation and consumer products. We also provide our optoelectronic devices and electronics manufacturing services to OEM customers and to our own Security and Healthcare divisions. Revenues from external customers in our Optoelectronics and Manufacturing division accounted for 24% and 22% of our total consolidated revenues for the six months ended December 31, 2023 and 2024, respectively.

​

Healthcare Division. Through our Healthcare division, we design, manufacture, market and service patient monitoring, cardiology and remote monitoring, and connected care systems globally for sale primarily to hospitals and medical centers. Our products monitor patients in critical, emergency and perioperative care areas of the hospital and provide information, through wired and wireless networks, to physicians and nurses who may be at the patient’s bedside, in another area of the hospital or even outside the hospital. Revenues from our Healthcare division accounted for 12% and 11% of our total consolidated revenues for the six months ended December 31, 2023 and 2024, respectively.

​

Trends and Uncertainties

​

The following is a discussion of certain trends and uncertainties that we believe have influenced, and may continue to influence, our results of operations.

​

Global Economic Considerations. Our products and services are sold in numerous countries worldwide, with a large percentage of our sales generated outside the United States. We are exposed to and impacted by global macroeconomic factors, U.S. and foreign government policies and foreign exchange fluctuations. There is uncertainty surrounding macroeconomic factors in the U.S. and globally characterized by supply chain disruptions, inflationary pressure, and labor shortages. Increasing diplomatic and trade friction between the U.S. and China has also created significant uncertainty in the global economy. These global macroeconomic factors, coupled with political unrest internationally and the volatile U.S. political climate, resulting from the recent U.S. presidential election and congressional seat changes, have increased economic uncertainty and could impact demand for certain of our products and services. Conflicts in Gaza and nearby regions have created political and economic uncertainty in the Middle East. Also, the continued conflict between Russia and Ukraine and the sanctions imposed in response to this conflict have increased global economic and political uncertainty. We do not know how long this uncertainty will continue. These factors could have a material adverse effect on our business, results of operations and financial condition.

Global Trade. The current domestic and international political environment, including in relation to recent and further potential changes by the U.S. and other countries in policies on global trade and tariffs, have resulted in uncertainty surrounding the future state of the global economy and global trade. This uncertainty is exacerbated by sanctions imposed by the U.S. government against certain businesses and individuals in select countries. Continued or increased uncertainty regarding global trade due to these or other factors may require us to modify our current business practices and could have a material adverse effect on our business, results of operations and financial condition.

​

Healthcare Considerations. Our Healthcare division experienced some increased demand for its patient monitoring products as a result of the COVID-19 pandemic during the earlier stages of the pandemic. Certain hospitals are facing significant financial pressure as supply chain constraints and inflation drive up operating costs, and higher interest rates make access to credit more expensive. Continuation of these macroeconomic conditions would likely have an adverse impact on hospitals’ spend on capital equipment and thereby could have a material adverse effect on our business, results of operations and financial condition.

Government Policies. Our results of operations and cash flows could be materially affected by changes in U.S. or foreign government legislative, regulatory or enforcement policies.

​

Russia’s Invasion of Ukraine. The invasion of Ukraine by Russia and the sanctions imposed in response to this conflict have increased global economic and political uncertainty. This has the potential to indirectly disrupt our supply chain and access to certain resources. While we have not experienced significant adverse impacts to date and will continue to monitor for any impacts and seek to mitigate disruption that may arise, we have certain research and development activities within Ukraine for our Healthcare division which have been somewhat impacted. The conflict also has increased the threat of malicious cyber activity from nation states and other actors.

26

Table of Contents

Currency Exchange Rates. On a year-over-year basis, currency exchange rates negatively impacted reported sales by approximately 0.8% for the six months ended December 31, 2024 compared to the six months ended December 31, 2023, primarily due to the strengthening of the U.S. dollar against other foreign currencies in 2024. Any strengthening of the U.S. dollar against foreign currencies would adversely impact our sales for the remainder of the year, and any further weakening of the U.S. dollar against foreign currencies would positively impact our sales for the remainder of the year.

Results of Operations for the Three Months Ended December 31, 2023 (Q2 Fiscal 2024) Compared to the Three Months Ended December 31, 2024 (Q2 Fiscal 2025) (amounts in millions)

​

Net Revenues

​

The table below and the discussion that follows are based upon the way in which we analyze our business. See Note 12 to the condensed consolidated financial statements for additional information about our business segments.

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Q2 |  | % of |  | Q2 |  | % of |  | ​ |  | ​ |
​ |  | Fiscal 2024 |  | Net Revenues |  | Fiscal 2025 |  | Net Revenues |  | $ Change |  | % Change |
Security |  | $ | 250.0 | ​ | 67.0 | % | $ | 290.0 | ​ | 69.1 | % | $ | 40.0 | ​ | 16.0 | %
Optoelectronics and Manufacturing | ​ | ​ | 81.4 | ​ | 21.8 | ​ | ​ | 85.0 | ​ | 20.2 | ​ | ​ | 3.6 | ​ | 4.4 | ​
Healthcare | ​ | ​ | 41.8 | ​ | 11.2 | ​ | ​ | 44.9 | ​ | 10.7 | ​ | ​ | 3.1 | ​ | 7.4 | ​
Total net revenues |  | $ | 373.2 | ​ | 100.0 | % | $ | 419.9 | ​ | 100.0 | % | $ | 46.7 | ​ | 12.5 | %

​

Revenues for the Security division during Q2 fiscal 2025 increased year-over-year due to increases in product and service revenues of approximately $36.8 million and $3.2 million, respectively. The increase in product revenues was primarily driven by growth in checkpoint screening systems, trace detections systems, and the acquired business further described in Note 2 to the condensed consolidated financial statements. The increase in service revenue was due primarily to an increase in the installed base of products.

Revenues for the Optoelectronics and Manufacturing division during Q2 fiscal 2025 increased year-over-year as a result of an increase in revenues in our contract manufacturing business.

Revenues for the Healthcare division during Q2 fiscal 2025 increased year-over-year primarily due to an increase in patient monitoring sales of $3.6 million partially offset by a decrease in cardiology sales of $0.5 million.

Gross Profit

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Q2 | ​ | % of | ​ | Q2 | ​ | % of | ​
​ |  | Fiscal 2024 |  | Net Revenues |  | Fiscal 2025 |  | Net Revenues |
Gross profit | ​ | $ | 141.3 | ​ | 37.9 | % | $ | 147.1 | ​ | 35.0 | %

​

Gross profit is impacted by sales volume and changes in overall manufacturing-related costs, such as raw materials and component costs, warranty expense, provision for inventory, freight, and logistics. Gross profit increased approximately $5.8 million in Q2 fiscal 2025 as compared to the prior year driven by the increase in sales. The gross margin in Q2 fiscal year 2025 decreased as compared to Q2 fiscal year 2024 as the prior year comparable quarter had a very favorable mix of Security division revenues, resulting in a higher gross margin.

Operating Expenses

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Q2 |  | % of |  | Q2 | ​ | % of | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Fiscal 2024 |  | Net Revenues |  | Fiscal 2025 |  | Net Revenues |  | $ Change |  | % Change | ​
Selling, general and administrative |  | $ | 71.6 | ​ | 19.2 | % | $ | 70.7 | ​ | 16.8 | % | $ | (0.9) | ​ | (1.3) | %
Research and development | ​ |  | 16.3 | ​ | 4.4 | ​ | ​ | 18.3 | ​ | 4.4 | ​ | ​ | 2.0 | ​ | 12.3 | ​
Restructuring and other charges, net | ​ |  | 1.0 | ​ | 0.3 | ​ | ​ | 0.2 | ​ | 0.0 | ​ | ​ | (0.8) | ​ | (80.0) | ​
Total operating expenses | ​ | $ | 88.9 | ​ | 23.9 | % | $ | 89.2 | ​ | 21.2 | % | $ | 0.3 | ​ | 0.3 | %

​

Selling, general and administrative. Our significant selling, general and administrative (“SG&A”) expenses include employee compensation, sales commissions, travel, professional services, marketing expenses, foreign currency translation, and depreciation and amortization expense. SG&A expense for Q2 fiscal 2025 was comparable to the same prior-year period.

27

Table of Contents

Research and development. Research and development (“R&D”) expenses include research related to new product development and product enhancements. R&D expenses increased $2.0 million in Q2 fiscal 2025 as compared to Q2 fiscal 2024 driven by increased compensation costs to support new product development initiatives primarily in our Security division.

Restructuring and other charges. Restructuring and other charges generally consist of costs relating to reductions in our workforce, facilities consolidation, costs related to acquisition activity, and other non-recurring charges. During Q2 fiscal 2025, restructuring and other charges were $0.2 million primarily for acquisition activity. During Q2 fiscal 2024, restructuring and other charges were $1.0 million, which included $0.2 million in acquisition related costs, $0.3 million in legal charges, $0.3 million for facility closure costs for operational efficiency activities, and $0.2 million for employee terminations.

Interest and Other Expense, Net

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Q2 | ​ | % of | ​ | Q2 | ​ | % of |
​ |  | Fiscal 2024 |  | Net Revenues |  | Fiscal 2025 |  | Net Revenues |
Interest and other expense, net | ​ | $ | 6.5 | ​ | 1.7 | % | $ | 8.6 | ​ | 2.0 | %

​

Interest and other expense, net. For Q2 fiscal 2025, interest and other expense, net was $8.6 million as compared to $6.5 million in the same prior-year period. This increase was driven by higher average levels of borrowings primarily to support the increase in working capital associated with the growth in revenues, business acquisition activity, and for the repurchase of approximately $80 million of common stock in July 2024. Interest expense in Q2 fiscal 2025 and Q2 fiscal 2024 includes a benefit from the interest rate swap of $0.6 million and $0.9 million, respectively.

Income taxes. The effective tax rate for a particular period varies depending on a number of factors, including (i) the mix of income earned in various tax jurisdictions, each of which applies a unique range of income tax rates and income tax credits, (ii) changes in previously established valuation allowances for deferred tax assets (changes are based upon our current analysis of the likelihood that these deferred tax assets will be realized), (iii) the level of non-deductible expenses, (iv) certain tax elections (v) tax holidays granted to certain of our international subsidiaries and (vi) discrete tax items. For Q2 fiscal 2025 and 2024, we recognized a provision for income taxes of $11.5 million and $9.2 million, respectively. The effective tax rates for Q2 fiscal 2025 and 2024 were 23.3% and 20.2%, respectively. During Q2 fiscal 2025, we recognized a net discrete tax benefit of $0.3 million related to equity-based compensation under ASU 2016-09. During Q2 fiscal 2024, we recognized a net discrete tax benefit of $0.2 million related to equity-based compensation under ASU 2016-09 and a benefit of $2.3 million from changes in prior year estimates.

Results of Operations for the Six Months Ended December 31, 2023 (YTD Q2 Fiscal 2024) Compared to the Six Months Ended December 31, 2024 (YTD Q2 Fiscal 2025) (amounts in millions)

Net Revenues

The table below and the discussion that follows are based upon the way in which we analyze our business. See Note 12 to the condensed consolidated financial statements for additional information about our business segments.

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | YTD Q2 | ​ | % of | ​ | YTD Q2 | ​ | % of | ​ | ​ | ​ | ​ | ​ |
​ |  | Fiscal 2024 |  | Net Revenues |  | Fiscal 2025 |  | Net Revenues |  | $Change |  | % Change |
Security | ​ | $ | 414.6 |  | 63.6 | % | $ | 514.3 |  | 67.3 | % | $ | 99.7 |  | 24.0 | %
Optoelectronics and Manufacturing | ​ |  | 158.2 |  | 24.2 | ​ |  | 167.6 |  | 22.0 | ​ |  | 9.4 |  | 5.9 | ​
Healthcare | ​ |  | 79.6 |  | 12.2 | ​ |  | 82.0 |  | 10.7 | ​ |  | 2.4 |  | 3.0 | ​
Total net revenues | ​ | $ | 652.4 |  | 100.0 | % | $ | 763.9 |  | 100.0 | % | $ | 111.5 |  | 17.1 | %

​

Revenues for the Security division during YTD Q2 fiscal 2025 increased year-over-year due to an increase in product and service revenues of approximately $88.8 million and $10.9 million, respectively. The increase in product revenues was primarily driven by growth in cargo and vehicle inspection systems, checkpoint screening systems, trace detections systems, and the acquired business further described in Note 2 to the condensed consolidated financial statements. The increase in service revenue was due primarily to an increase in the installed base of products.

28

Table of Contents

Revenues for the Optoelectronics and Manufacturing division during YTD Q2 fiscal 2025 increased year-over year as a result of an increase in revenue in our contract manufacturing business of approximately $11.2 million, partially offset by a decrease in revenue of approximately $1.8 million in our optoelectronics business.

Revenues for the Healthcare division during YTD Q2 fiscal 2025 increased year-over-year due to an increase in patient monitoring sales of $2.3 million, service revenue of $0.8 million and accessories revenue of $0.7 million, partially offset by a reduction in cardiology sales of $1.5 million.

Gross Profit

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | YTD Q2 | ​ | % of | ​ | YTD Q2 | ​ | % of |
​ |  | Fiscal 2024 |  | Net Revenues |  | Fiscal 2025 |  | Net Revenues |
Gross profit | ​ | $ | 240.0 |  | 36.8 | % | $ | 268.7 |  | 35.2 | %

​

Gross profit increased approximately $28.7 million in YTD Q2 fiscal 2025 as compared to the prior year driven by the increase in sales. The gross margin decreased as compared to the prior year comparable period as the prior year period had a very favorable mix of Security division revenues, resulting in a higher gross margin.

​

Operating Expenses

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | YTD Q2 | ​ | % of | ​ | YTD Q2 | ​ | % of | ​ | ​ | ​ | ​ |
​ |  | Fiscal 2024 |  | Net Revenues |  | Fiscal 2025 |  | Net Revenues |  | $Change |  | % Change |
Selling, general and administrative | ​ | $ | 131.4 |  | 20.1 | % | $ | 142.9 |  | 18.7 | % | 11.5 |  | 8.8 | %
Research and development | ​ |  | 32.3 |  | 5.0 | ​ |  | 36.0 |  | 4.7 |  | 3.7 |  | 11.5 | ​
Restructuring and other charges, net | ​ |  | 1.5 |  | 0.2 | ​ |  | 1.4 |  | 0.2 |  | (0.1) |  | (6.7) | ​
Total operating expenses | ​ | $ | 165.2 |  | 25.3 | % | $ | 180.3 |  | 23.6 | % | 15.1 |  | 9.1 | %

​

Selling, general and administrative. SG&A expense for YTD Q2 fiscal 2025 was $11.5 million higher than in the same prior-year period, primarily due to increased employee compensation, changes in fair value of certain contingent earnout liabilities, and unfavorable impact of foreign currency exchange rates in YTD Q2 fiscal 2025 compared to the same prior-year period.

Research and development. R&D expense for YTD Q2 fiscal 2025 increased $3.7 million over the same prior-year period driven by increased compensation costs to support new product development initiatives primarily in our Security division.

Restructuring and other charges. Restructuring and other charges were comparable in YTD Q2 fiscal 2025 as in the same prior-year period.

Interest and Other Expense, Net

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | YTD Q2 | ​ | % of | ​ | YTD Q2 | ​ | % of |
​ |  | Fiscal 2024 |  | Net Revenues |  | Fiscal 2025 |  | Net Revenues |
Interest and other expense, net | ​ | $ | 12.3 |  | 1.9 | % | $ | 16.0 |  | 2.1 | %

​

Interest and other expense, net. The increase in interest and other expense, net was driven by higher average levels of borrowings primarily to support the increase in working capital associated with the growth in revenues, business acquisition activity, and for the repurchase of approximately $80 million of common stock in July 2024. Interest expense for YTD Q2 fiscal 2025 and 2024 included a benefit of $1.5 million and $1.8 million, respectively, from the interest rate swap.

Income taxes. The effective tax rate for a particular period varies depending on a number of factors, including (i) the mix of income earned in various tax jurisdictions, each of which applies a unique range of income tax rates and income tax credits, (ii) changes in previously established valuation allowances for deferred tax assets (changes are based upon our current analysis of the likelihood that these deferred tax assets will be realized), (iii) the level of non-deductible expenses, (iv) certain tax elections (v) tax holidays granted to certain of our international subsidiaries and (vi) discrete tax items. For YTD Q2 fiscal 2025 and 2024, we recognized a provision for income taxes of $16.6 million and $13.2 million, respectively. The effective tax rates for YTD Q2 fiscal 2025 and 2024 were 22.9% and 21.0%, respectively. For YTD Q2 fiscal 2024, we recognized a discrete tax benefit of $0.6 million related to equity-based compensation

29

Table of Contents

under ASU 2016-09 and a benefit of $2.3 million from changes in prior year tax estimates. For YTD Q2 fiscal 2025, we recognized a discrete tax benefit of $0.8 million related to equity-based compensation under ASU 2016-09.

Liquidity and Capital Resources

​

Our principal sources of liquidity are our cash and cash equivalents, cash generated from operations and our credit facilities. Cash and cash equivalents totaled $101.6 million at December 31, 2024, an increase of $6.2 million, or 7%, from $95.4 million at June 30, 2024. We currently anticipate that our available funds, credit facilities and cash flow from operations will be sufficient to meet our operational cash needs for the next 12 months and the foreseeable future beyond that. In addition, we anticipate that cash generated from operations, without repatriating earnings from our non-U.S. subsidiaries, and our credit facilities will be sufficient to satisfy our obligations in the U.S.

In July 2024, we issued an aggregate of $350.0 million principal amount of 2.25% convertible senior notes due in August 2029. In connection with the issuance of the 2029 Notes, we repurchased 531,314 shares of our common stock for approximately $80 million.

Our credit facility comprises a term loan and a $600 million revolving credit facility, which includes a $300 million sub-facility for letters of credit. As of December 31, 2024, there was $131.9 million outstanding under the term loan, $236.0 million outstanding under our revolving credit facility and $78.6 million of outstanding letters of credit. As of December 31, 2024, the total amount available under our revolving credit facility was $285.4 million. See Note 8 to the consolidated financial statements for further discussion.

Cash Provided by (Used in) Operating Activities. Cash flows from operating activities can fluctuate significantly from period to period, as net income, adjusted for non-cash items, and working capital fluctuations impact cash flows. For YTD Q2 fiscal 2025, cash provided by operations was $15.4 million compared to cash used in operations of $6.4 million in the comparable prior-year period. The net change in cash flows from operating activities was due primarily to favorable changes in net working capital and higher net income for YTD Q2 fiscal 2025 over the comparable prior-year period.

Cash Used in Investing Activities. Net cash used in investing activities was $97.6 million for YTD Q2 fiscal 2025 as compared to $21.8 million in the same prior year period. We used $75.5 million for a business acquisition in September 2024, compared to $9.0 million in the first half of fiscal year 2024. Capital expenditures for YTD Q2 fiscal year 2025 were $13.2 million compared to $8.7 million in the same prior-year period. Expenditures for intangible and other assets for YTD Q2 fiscal year 2025 were $9.1 million compared to $8.4 million in the same prior-year period.

Cash Provided by Financing Activities. Net cash provided by financing activities was $89.2 million for YTD Q2 fiscal 2025, compared to $77.1 million during the same prior-year period. The change in cash flows from financing activities was primarily due to net proceeds of $340.5 million from the 2029 Notes, partially offset by (1) net repayment of $148.0 million on our credit facility and (2) repurchase of common stock of $80.4 million. Taxes paid related to net share settlement of equity awards were $22.6 million during YTD Q2 fiscal 2025 compared to $23.0 million in the same prior-year period.

Borrowings

​

See Note 8 to the condensed consolidated financial statements for a detailed discussion regarding our revolving credit facility and other borrowings.

​

Cash Held by Foreign Subsidiaries

​

Our cash and cash equivalents totaled $101.6 million at December 31, 2024. Of this amount, approximately 77% was held by our foreign subsidiaries and subject to repatriation tax considerations. These foreign funds were held primarily by our subsidiaries in India, the United Kingdom, and to a lesser extent in Malaysia, Singapore, and Canada, among other countries. We intend to permanently reinvest certain earnings from foreign operations, and we currently do not anticipate that we will need this cash in foreign countries to fund our U.S. operations. In the event we repatriate cash from certain foreign operations and if taxes have not previously been withheld on the related earnings, we would provide for withholding taxes at the time we change our intention with regard to the reinvestment of those earnings.

​

30

Table of Contents

Issuer Purchase of Equity Securities

​

We did not repurchase any shares of common stock during the second quarter of fiscal year 2025.

​

Contractual Obligations

​

During the six months ended December 31, 2024, there were no material changes outside the ordinary course of business to the information regarding specified contractual obligations contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024. See Notes 1, 6, 8 and 10 to the condensed consolidated financial statements for additional information regarding our contractual obligations.

​

Recent Accounting Pronouncements

​

From time to time, new accounting pronouncements are issued by the FASB and other regulatory bodies that are adopted as of the specified effective dates. Unless otherwise discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on our Consolidated Financial Statements upon adoption. As discussed in Note 1, we are currently evaluating the potential impact on financial statement disclosures upon future adoption of ASU 2023 - 07 and ASU 2023 - 09. There were no new pronouncements adopted in the second quarter of fiscal year 2025.

​

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

​

For a discussion of our exposure to market risk, refer to our market risk disclosures set forth in Part II, Item 7A “Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024. There have been no material changes in our exposure to market risk during the six months ended December 31, 2024 from that described in the Annual Report.

​

ITEM 4. CONTROLS AND PROCEDURES

​

Evaluation of Disclosure Controls and Procedures

​

As of December 31, 2024, the end of the period covered by this report, our management, including our Chief Executive Officer and our Chief Financial Officer, reviewed and evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) of the Exchange Act). Based upon management’s review and evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the SEC and is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

​

Changes in Internal Control over Financial Reporting

​

There were no changes in our internal control over financial reporting during the second quarter of fiscal 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

​

Limitations on Effectiveness of Controls and Procedures

​

In designing and evaluating our controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud within the Company have been detected.

​

​

31

Table of Contents

PART II—OTHER INFORMATION

​

ITEM 1. LEGAL PROCEEDINGS

​

From time to time, we are subject to legal proceedings, claims, and litigation arising in the ordinary course of our business or otherwise. More information regarding legal proceedings in which we are involved can be found under Note 10, “Commitments and Contingencies” of the Notes to the Consolidated Financial Statements in Part I, Item 1 of this Report, which is incorporated by reference into this Item 1.

​

ITEM 1A. RISK FACTORS

​

The discussion of our business, financial condition and results of operations in this Quarterly Report on Form 10-Q for the period ended December 31, 2024 should be read together with the risk factors contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024, filed with the SEC on August 29, 2024, which describe various risks and uncertainties that could materially affect our business, financial condition and results of operations in the future. There have been no material changes to the risk factors included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024.

​

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

​

See Issuer Purchases of Equity Securities discussion under Part I, Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations, which is incorporated by reference into this Item 2.

​

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

​

None

​

ITEM 4. MINE SAFETY DISCLOSURES

​

Not applicable

​

ITEM 5. OTHER INFORMATION

​

Rule 10b5 - 1 Trading Plans

​

Our directors and officers (as defined in Rule 16a-1 under the Exchange Act) may from time to time enter into plans or other arrangements for the purchase or sale of our shares that are intended to satisfy the affirmative defense conditions of Rule 10b5-1 (c) or may represent a non-Rule 10b5-1 trading arrangement under the Exchange Act. During the second quarter of fiscal 2025, none of our directors or officers informed us of the adoption, modification or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” as those terms are defined in Regulation S-K, Item 408.

​

​

32

Table of Contents

ITEM 6. EXHIBITS

​

Exhibit Number |  | Description
​ | ​ | ​
10.1 | ​ | Amendment dated December 12, 2024 to Amended and Restated Employment Agreement between Ajay Mehra and OSI Systems, Inc. (1)
​ | ​ | ​
31.1 | ​ | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
​ | ​ | ​
31.2 | ​ | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
​ | ​ | ​
32.1 | ​ | Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
​ | ​ | ​
32.2 | ​ | Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
​ | ​ | ​
101.INS | ​ | XBRL Instance Document
​ | ​ | ​
101.SCH | ​ | Inline XBRL Taxonomy Extension Schema
​ | ​ | ​
101.CAL | ​ | Inline XBRL Taxonomy Extension Calculation Linkbase
​ | ​ | ​
101.DEF | ​ | Inline XBRL Taxonomy Extension Definition Linkbase
​ | ​ | ​
101.LAB | ​ | Inline XBRL Taxonomy Extension Label Linkbase
​ | ​ | ​
101.PRE | ​ | Inline XBRL Taxonomy Extension Presentation Linkbase
​ | ​ | ​
104 | ​ | Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)

(1)Previously filed with our Current Report on Form 8-K filed on December 13, 2024.

​

33

Table of Contents

Signatures

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized, in the City of Hawthorne, State of California on the 24th day of January 2025.

​

​ | ​ | ​
​ | OSI SYSTEMS, INC.
​ | ​ | ​
​ | By: | /s/ Ajay Mehra
​ | ​ | Ajay Mehra
​ | ​ | President and Chief Executive Officer
​ | ​ | (Principal Executive Officer)
​ | ​ | ​
​ | By: | /s/ Alan Edrick
​ | ​ | Alan Edrick
​ | ​ | Executive Vice President and Chief Financial Officer
​ | ​ | (Principal Financial Officer)
​ | ​ | ​
​ | By: | /s/ Cary Okawa
​ | ​ | Cary Okawa
​ | ​ | Chief Accounting Officer
​ | ​ | (Principal Accounting Officer)

​

​

34